tappAS: a comprehensive computational framework for the analysis of the functional impact of differential splicing

Lorena de la Fuente[1,a,+], Ángeles Arzalluz-Luque[2], Manuel Tardáguila[3,a,§], Manuel Tardáguila, Héctor del Risco[3,], Cristina Martí[1], Sonia Tarazona[2], Pedro Salguero[1], Raymond Scott[3], Ana Alastrue-Agudo[4], Pablo Bonilla[4], Jeremy Newman[5,6], Lauren McIntyre[5,7], Victoria Moreno-Manzano[4,b], Ana Conesa[3,5,b]

[1]Genomics of Gene Expression Laboratory, Prince Felipe Research Center, Valencia, Spain

[2]Department of Statistics and Operational Research, Polytechnical University of Valencia, Valencia, Spain

[3]Department of Microbiology and Cell Science, Institute for Food and Agricultural Sciences, University of Florida, Gainesville, Florida, USA

[4]Neural Regeneration Laboratory, Prince Felipe Research Center, Valencia, Spain

[5]Genetics Institute, University of Florida, Gainesville, Florida, USA

[6]Department of Pathology, University of Florida, Gainesville, Florida, USA

[7]Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, Florida, USA

[+]Present Address: Bioinformatics Unit, IIS Fundación Jiménez Díaz, Madrid, Spain

[§]Present Address: Human Genetics Department, Wellcome Trust Sanger Institute, Hinxton (Cambridge), UK

[a]These authors contributed equally to this work.

[b] These authors jointly supervised this work.

Corresponding author: aconesa@ufl.edu

Abstract

Traditionally, the functional analysis of gene expression data has used pathway and network enrichment algorithms. These methods are usually gene rather than transcript centric and hence fall short to unravel functional roles associated to posttranscriptional regulatory mechanisms such as Alternative Splicing (AS) and Alternative PolyAdenylation (APA), jointly referred here as Alternative Transcript Processing (AltTP). Moreover, short-read RNA-seq has serious limitations to resolve full-length transcripts, further complicating the study of isoform expression. Recent advances in long-read sequencing open exciting opportunities for studying isoform biology and function. However, there are no established bioinformatics methods for the functional analysis of isoform-resolved transcriptomics data to fully leverage these technological advances. Here we present a novel framework for Functional Iso-Transcriptomics analysis (FIT). This framework uses a rich isoform-level annotation database of functional domains, motifs and sites –both coding and non-coding- and introduces novel analysis methods to interrogate different aspects of the functional relevance of isoform complexity. The Functional Diversity Analysis (FDA) evaluates the variability at the inclusion/exclusion of functional domains across annotated transcripts of the same gene. Parameters can be set to evaluate if AltTP partially or fully disrupts functional elements. FDA is a measure of the potential of a multiple isoform transcriptome to have a functional impact. By combining these functional labels with expression data, the Differential Analysis Module evaluates the relative contribution of transcriptional (i.e. gene level) and post-transcriptional (i.e. transcript/protein levels) regulation on the biology of the system. Measures of isoform relevance such as Minor Isoform Filtering, Isoform Switching Events and Total

Isoform Usage Change contribute to restricting analysis to biologically meaningful changes. Finally, novel methods for Differential Feature Inclusion, Co-Feature Inclusion, and the combination of UTR-lengthening with Alternative Polyadenylation analyses carefully dissects the contextual regulation of functional elements resulting from differential isoforms usage. These methods are implemented in the software tappAS, a user-friendly Java application that brings FIT to the hands of non-expert bioinformaticians supporting several model and non-model species. tappAS complements statistical analyses with powerful browsing tools and highly informative gene/transcript/CDS graphs.

We applied tappAS to the analysis of two mouse Neural Precursor Cells (NPCs) and Oligodendrocyte Precursor Cells (OPCs) whose transcriptome was defined by PacBio and quantified by Illumina. Using FDA we confirmed the high potential of AltTP regulation in our system, in which 90% of multi-isoform genes presented variation in functional features at the transcript or protein level. The Differential Analysis module revealed a high interplay between transcriptional and AltTP regulation in neural development, mainly controlled by differential expression, but where AltTP acts the main driver of important neural development biological mechanisms such as vesicle trafficking, signal transduction and RNA processing. The DFI analysis revealed that, globally, AltTP increased the availability of functional features in differentiated neural cells. DFI also showed that AltTP is a mechanism for altering gene function by changing cellular localization and binding properties of proteins, via the differential inclusion of NLS, transmembrane domains or DNA binding motifs, for example. Some of these findings were experimentally validated by others and us.

In summary, we propose a novel framework for the functional analysis of transcriptomes at isoform resolution. We anticipate the tappAS tool will be an important resource for the adoption of the Functional Iso-Transcriptomics analysis by functional genomics community.

Introduction

One of the most exciting aspects of transcriptome biology is the contextual adaptability of eukaryotic transcriptomes and proteomes by Alternative Splicing (AS), Alternative PolyAdenylation (APA), and Alternative Transcription Start Sites (ATSS) mechanisms, jointly referred to as Alternative Transcript Processing (AltTP). These three processes determine which transcripts (aka, isoforms) are produced for a given gene. Alternate transcripts may differ in structure and in function, as well as in cell specificity, and within cell spatio-temporal deployment.

The study of AltTP has experimentally been addressed either via molecular characterization of the functionality of specific isoforms from single genes[1,2], or by computationally approaches aiming to find global patterns and infer their potential biological significance *in silico*[3,4]. Computational AltTP analysis has focused on the study of processing *events*, namely exon spiking, intron retention, alternative transcript start (TSS) and termination sites (TTS), nonsense-mediated decay (NMD) and changes in the inclusion/exclusion levels of different exons[5–8]. In parallel, molecular studies have been conducted to understand the mechanisms behind the dynamic changes in event patterns, identifying a large number of RNA binding proteins as regulators of AltTP[9–14]. In response to the recognition of the biological importance of AltTP, bioinformatics tools have been developed to analyze the structural and regulatory aspects of AltTP events and have contributed to the description and understanding of AltTP (reviewed in[15]).

While some discrepancy exist on the actual functional role of transcript isoform diversity[16,17]. AltTP has been proven to be implicated in differentiation[18–20], tissue

identity[21,22], development[13,23], stress response[24] and disease[25–28]. Beyond these well known effects, several studies have shown enrichment of spliced exons in disordered regions mediating new protein interactions[29] and remodeling of protein-protein interaction in a tissue-specific manner[30,31]. In other work, AS was shown to regulate domains leading to the rewiring of PPI networks in cancer[32]. Similarly, APA has been postulated as a mechanism to escape microRNA regulation by shortening 3' UTR regions[33,34], alternative TSS are believed to regulate the inclusion of Upstream Open Reading Frames (uORFs) that control translational rates[35–37] and NMD has been proposed to regulate gene expression in cancer and neural systems[38,39].

Traditionally, computational approaches such as enrichment and network analysis have been used to study the functional aspects of transcriptional changes[40–43] and these have been instrumental for the characterization of transcriptome biology. However, these methods operate at the gene level and are not adapted to study the functional readout of AltTP. Much of the work done to answer transcriptome-wide questions on the functional role of AltTP has involved *ad hoc* computational pipelines applied to specific biological systems or address only particular types of events[44–49]. Recently, Exon Ontology[50] was proposed as a resource to study functional enrichment of exon sets based on their annotation with protein functional domains. Using this tool, authors were able to show different molecular functionalities directly associated to changes in exon inclusion levels between epithelial and mesenchymal cells. However, this analysis does not reveal how transcripts combine exons to provide distinct functional elements, nor addresses the analysis of regulatory signals at alternative UTRs. In general, the field lacks computational tools tailored to the study

of the functional aspects of isoform expression regulation, limiting advances in our understanding of the functional impact of AltTP.

One important reason behind the lack of functional perspective in splicing-dedicated bioinformatics tools is the inability of RNAseq to correctly capture isoform expression[51]. Recently, third generation sequencing technologies have demonstrated their power in detecting full-length transcript[52–56] and identifying expressed isoforms. Options for quantification are found in the combination with short-reads[55] or the utilization of the newest high throughput instruments. As more scientists engage in expression studies that use these new platforms with the goal of identifying differences between conditions in isoform usage, there is a growing need of tools to easily and quickly interpret isoform differences in the context of their potential functional impact.

Here we present a novel computational framework for the study AltTP from a functional perspective, introducing the Functional Iso-Transcriptomics (FIT) analysis approach. This framework uses a rich isoform-level annotation database of functional domains, motifs and sites –both coding and non-coding-, that are mined by novel analysis methods that interrogate different aspects of the functional load associated to isoform complexity and expression regulation. These methods are implemented in the software tappAS (http://tappas.org), a user-friendly Java application that brings FIT to the hands of transcriptome scientists by supporting several model and non-model species. tappAS complements statistical analyses with powerful browsing tools and highly informative gene/transcript/CDS graphs. As a proof of principle, we

applied tappAS to the analysis of two mouse neural cell types, Neural Precursor Cells (NPCs) and Oligodendrocyte Precursor Cells (OPCs), whose transcriptome was defined by PacBio and quantified by Illumina[57]. tappAS easily recapitulates a great deal of the existing knowledge on AltTP function, as well as provide new functional insights. We anticipate that the tappAS framework will be widely applied in a variety of fields, and that its user-friendliness will promote the adoption of the FIT approach by researchers with different levels of computational skills.

Results

tappAS is a comprehensive tool to investigate potential functional consequences of AltTP

Functionality	Description		Illustration/formula
Analyses			
Functional Diversity Analysis (FDA)	Qualitative assessment of the functional potential of AltTP in a given system or dataset. Performed by feature ID, or by gene.	Positional approach: for positional features that need to be evaluated by comparing genomics coordinates across isoforms (e.g. UTRs).	
		Presence/absence approach: for non-positional features that need to be evaluated by presence/absence of annotation (e.g. NMD transcript status).	
Differential Expression (DE)	Transcripts (DIE): computes DE of transcript expression (tappAS input values).		
	Genes (DGE): aggregates transcript expression levels per gene to compute DE.		
	CDS (DCE): aggregates transcript expression levels per CDS to compute DE.		
Differential Isoform Usage (DIU)	Transcripts: test on the transcript:condition interaction per gene.		
	CDS (Differential Coding region Usage, DCU): Aggregates transcript expression levels per CDS to test transcript:condition interaction per gene.		
Differential Feature Inclusion (DFI)	For each functional feature in a gene, expression is collapsed to estimate the relative feature inclusion ratio with respect to absolute gen expression levels. A test is performed on the variant:condition interaction.	Positional approach	
		Presence/absence approach	
		Combined approach	

Co-DFI	For each pair of functional features marked as DFI in more than 5 genes, count the number of genes where both are differentially included.	Co-inclusion: No. of genes where the including and excluding variants are major in the same conditions.	
		Mutual exclusion: No. of genes where the including and excluding variants are major in opposite conditions.	
Differential polyadenylation (DPA)	For the distal (dPA) and proximal (pPA) polyA sites in a gene, expression is collapsed to sum expression of distal and proximal-expressing isoforms. A test is performed on the variant:condition interaction.		
3'UTR lengthening analysis	Provides a relative isoform usage-weighted mean 3'UTR length per time-point/condition.		$\overline{UTR_w} = \frac{\sum_{i=1}^{n} U_{ig} \cdot UTR_{ig}}{\sum_{i=1}^{n} UTR_{ig}}$
Metrics and pre-processing steps			
Feature Inclusion (FI) levels	Ratio between the sum of expression of all isoforms containing a feature and the total feature of a gene, calculated for a given condition/time-point.		$FI_{fg} = \frac{EInc_{f_g}}{EInc_{f_g} + EExc_{f_g}}$
Distal Poly-A Site Usage (DPAU)	Ratio between the sum of expression of all isoforms containing the distal polyA site and the total polyA expression of a gene, calculate for a given condition/time-point.		$DPAU = \frac{E_{dPA}}{E_{dPA} + E_{pPA}}$
Minor isoform filtering	Removes minor isoforms to avoid spurious (i.e. false-positive) DFI and DIU results.	By fold change: Removes from DIU/DCU transcript isoforms with more than a 2-fold (default) expression difference compared to the most expressed isoform.	
		By relative expression: Removes DIU/DCU transcript isoforms that account for less than 10% (default) of the total gene expression.	
Switching event	DIU: a gene changes its most expressed transcript isoform, i.e. the major isoform (the one with the highest overall mean expression) becomes minor in at least one time-point/condition.		
	DFI: a feature changes its inclusion levels from a		

	predominant to a minor position in at least one time-point/condition. DPA: a polyA site changes its usage levels from a predominant to a minor position in at least one time-point/condition.	
Feature-favoured condition	Conditions/time points where inclusion of a given feature, in DFI analysis, or distal polyA site usage, in the case of DPA, are promoted.	
Total change	Measures the magnitude (%) of the redistribution of expression between isoforms of a gene across all pairs of conditions/time-points.	$\sum_{i=1}^{n} \left\| \overbrace{\frac{E_{1ig}}{\sum_{i=1}^{n} E_{1ig}}}^{\text{Isoform Usage C1}} - \overbrace{\frac{E_{2ig}}{\sum_{i=1}^{n} E_{2ig}}}^{\text{Isoform Usage C2}} \right\| \times 0.5$

Table 1: Main analyses and metrics of tappAS.

tappAS analyses use a species-specific gff3-like file containing isoform-level, positionally-resolved, annotation features (see Methods). These labels describe functional motifs, domains and sites both at the CDS and the UTRs of transcripts, and are generated via the integration species-available databases and sequence-based prediction tools that gather functional and structural data. For our mouse example, 20 functional categories were retrieved (Supplementary Table 1). tappAS joins transcript-level expression data with this extensive annotation database and a wide array of traditional and novel analysis algorithms (Table 1) to create a comprehensive framework for the study of the functional impact of AltTP.

tappAS analysis can be divided into three Modules, each one targeting a different aspect in the study of AltTP biology (Figure 1). Module I includes Functional Diversity Analysis (FDA), which evaluates the functional regulatory potential of AltTP by interrogating the varying status of individual features across isoforms of the same gene (Figure 1). This includes analysis by gene (assessing the varying status of

individual genes for each functional feature category) and by feature ID (assessing the number of genes for which a particular feature is differentially present across isoforms). Depending on the feature, varying status is evaluated by genomic position (positional approach) or by presence/absence (presence approach) (Table 1, Methods). Module II can be used to understand the relative contribution of transcriptional and post-transcriptional regulation in the system under study by comparing Differential Isoform Usage (DIU, transcript level) or Differential Coding sequence Usage (DCU, protein level) with Differential Gene Expression (DGE) results, and by performing subsequent enrichment analyses. Finally, Module III includes methods to assess the context-dependent differential inclusion of annotated functional elements: Differential Feature Inclusion (DFI) of coding and non-coding elements, Differential PolyAdenylation (DPA) and 3'UTR lengthening analysis (3UL). Furthermore, a subsequent co-Differential Feature Inclusion (co-DFI) analysis can detect sets of features that are coordinately included. DPA and 3'UTR lengthening analyses can be combined to study which genes are regulated via alternative polyadenylation (APA) and 3'UTR length. Importantly, any of the tappAS outputs described above can be coupled to Functional Enrichment[58] and Gene-Set Enrichment[59] analyses based on any of the functional categories included in tappAS annotation. Finally, tappAS' displays all annotated features as gene, transcript and protein graphical maps enabling for a visual evaluation of isoforms and their functional components. For more details on the methodology behind these analyses, see Online Methods.



Figure 1: Overview of tappAS modules for Functional Iso-Transcriptomics Analysis. Module 1 contains a novel qualitative approach to evaluate functional diversity of alternative isoforms. Module 2 implements Differential Expression and Differential Isoform Usage analyses to discriminate AltTP (post-transcriptional) from transcriptional regulation mechanisms. Module 3 includes newly-developed approaches to measure the functional impact of AltTP as changes in the inclusion of functional features, polyA site usage and UTR length.

Functional Diversity Analysis

One fundamental question about AltTP is how post-transcriptional regulation imprints functional complexity to transcriptomes. The potential of AltTP mechanisms to regulate gene function largely depends on whether transcript isoforms contain variation in their functional elements. In this case, modifications in their expression levels can effectively modulate functional changes. Applied to our murine neural transcriptomes, tappAS FD analysis identified ~70% of 2,341 multi-isoform genes that varied in the predicted proteins (Figure 2A, CDS variability). Variability at 3′ and 5′ UTR lengths occurred in ~ 60% of the genes (Figure 2A). The vast majority (78%) of UTR-varying genes also had CDS variation, suggesting that protein diversity may be coupled to RNA regulatory diversity. To illustrate, Figure 2C shows an example of a gene detected by tappAS as Alternative PolyAdenylation (APA), 5′UTR, 3′UTR and CDS-varying.

Nonsense-mediated decay (NMD) had the highest variation rate among transcript-level features, 95% (Figure 2B). Moreover, nearly all genes with NMD transcripts expressed protein-coding counterparts, indicating that NMD-targeted isoforms are co-expressed with functional isoforms in our neural system, likely regulating their abundance[38,39,60]. UTR-motif annotated genes showed a presence/absence varying rate of 55% and 90% for 3′ and 5′ UTR motifs, respectively (Figure 2B), and GU-rich elements (GREs) were the most significantly varying 3′UTR motif types (Supplementary Table 2). GREs have been associated to the stabilization of mRNAs[61] and also have been reported as targets of RNA-binding proteins (RBPs) such as CELFs[62]. Among the set of 160 genes with differential inclusion of GRE elements in

our neural system, tappAS identified splicing regulators such as *Rbm4* (Supplementary Figure 1A), involved in neurogenesis of the mouse embryonic brain[63], and *Tcf12* (Supplementary Figure 1B), known to play an important role in the control of proliferating neural stem cells and progenitor cells during neurogenesis[64].

FDA also identified la large number of miRNAs. An enrichment test was used to rank miRNAs that we more frequently varying at 3'UTRs (Supplementary Table 3). Interestingly, the top-five most significantly varying miRNAs include miR-335-3p, known to associate with oligodendrocyte differentiation[65], and mir-590-3p, which responds to retinoic acid and is strongly associated to proliferation and differentiation processes[66]. Since our NPCs and OPCs constitute differentiating primary cells, these results point towards a potential isoform-specific layer of expression regulation in neural differentiation via gain and loss of miRNA binding sites due to AltTP.

Regarding presence/absence FD analysis of protein-level features, signal peptides have the highest varying rate, followed by compositional bias regions and post-translational modifications (PTMs) (Figure 2B). However, most features involving functional variability within coding sequences are best studied via the FD positional approach (Table 1, Figure 2A), which reports cases where a functional feature is partially disrupted, suggesting functional modulation changes. Hence, considering positional variation, Intrinsically Disordered regions (IDRs) and PFAM domains present the highest rates of differential inclusion in multi-isoform genes annotated for these feature categories (~78% and ~70%, respectively; Figure 2A) when

compared to presence/absence variation (Figure 2B). IDRs have been reported to be frequently present in transcript regions affected by AltTP[29,67,68].

To understand which PFAM domain types have higher positional than presence varying rates, we interrogated this category at the ID level. Figure 2D shows the top-15 PFAM domains ranked by varying rate in our data, using both the positional and presence approaches. We observe that zinc fingers and KRAB-box domains tend to be totally contained in AS exons, as varying rates using the presence and positional approaches are only slightly different. Hence, domain skipping in these cases will result in elimination from the protein, while Kinase and RNA binding domains stand out at the positional FD analysis, indicating that AltTP mechanisms tend to partially disrupt these domains, possibly causing partial loss/change of function.

In summary, tappAS' FD analysis successfully catalogues the transcriptome's potential for AltTP-mediated functional diversity and, in our mouse neural system, reveals that ~90% of multi-isoform genes have protein or transcript-level functional features that vary across isoforms.



Figure 2: Functional Diversity Analysis (FDA) results. A) FDA results summary using the positional approach. The % of multi-isoform genes with the annotated feature in which at least one isoform is varying is shown. The numbers above the bars indicate the total no. of varying genes for that category. B) FDA results summary using the presence/absence approach. C) tappAS graphical representation of the transcript-level annotation for the *Dbt* gene, where 5'UTR, CDS and 3'UTR/Alternative polyadenylation variation can be observed. D) Comparison of position vs presence/absence approach FDA results for the ID-level analysis of variation in PFAM domains. Top-15 domain families ranked by total number of varying genes shown.

Multi-layered Analysis of Alternative Transcript Processing

Transcriptional and post-transcriptional (AltTP) regulation are regulatory mechanisms that either control total expression levels or differences in the relative isoform proportions, both contributing to regulate gene function. tappAS' Differential Module (Figure 1) is designed to dissect and compare these two regulatory layers.

Figure 3A shows the intersection of differential analysis results for our neural dataset. tappAS identified 1,205 genes differentially expressed between NPCs and OPCs (FDR<0.05, FC>1.5), while only 291 of them were also regulated by AltTP mechanisms, as revealed by DIU analysis (FDR<0.05). Interestingly, although these results showed that most DE multi-isoform genes were regulated exclusively at the transcriptional level, a group of 247 genes were solely affected by AltTP, meaning that ~50% of DIU genes underwent a redistribution of expression among their isoforms with no significant change in gene-level expression (example in Figure 3B). This suggests independent AltTP and gene expression regulatory mechanisms operating in our neural system. However, when a filter on isoform low relative abundance was applied (<10% of total gene expression), 110 genes lost DIU status, revealing that a fraction of DIU calls is composed by transcripts that barely contribute to total gene expression, and might not be functionally relevant (Supplementary Figure 2A). After DCU analysis (Table 1, FDR<0.05), we identified a group of 135 genes where differential usage of isoforms did not involve changes in coding sequence usage (see examples in Supplementary Figure 2B, comprehensive results in Supplementary Table 4). Finally, among 279 genes detected by both DIU and DCU analyses after filtering (and therefore significantly affected by AltTP), a relevant 35% undergo a major isoform switch (see Methods), (Table 1) between NPCs and OPCs (Figure 3A), meaning that a significant fraction of isoform usage differences between both cell types have the potential for a strong functional impact. In order to identify the most significantly AltTP-regulated candidates, we used joint evaluation of total usage change (Table 1, Online Methods), which constitutes a quantitative measure of DIU (i.e. the degree of isoform usage change for a given gene across conditions),

together with the identification of isoform switching events (Figure 3C). Specifically, most genes with isoform switching have total change >20%. Hence, switching can be used as criteria to prioritize candidates where AltTP has potentially higher impact on the functionality of the gene and are more interesting for experimental validation.

To evaluate the potential functional impact of AltTP relative to gene expression regulation, tappAS includes Functional Enrichment algorithms operating on all available functional databases and sets of differential features. For example, Gene Ontology-based Multi-Dimensional Gene Set Enrichment Analysis[69] of genes ranked by DE and DIU p-value is effective to directly compare enriched functions controlled by either mechanism. Figure 3D shows the top 25 enriched GO terms in this analysis. In this tappAS representation we readily appreciate that transcriptional regulation dominates in some important functions required for differentiation, as shown by preferential enrichment in cell cycle, spindle and chromosome-related terms. DE-regulation is also the main driver of some processes related to oligodendrocyte function, such lipid metabolism, likely related to myelination (Figure 3D). On the contrary, preferential regulation by AltTP is present for core of terms related to vesicle transport, in line with the known role of vesicle trafficking for polarity establishment and myelination[70–72], and with previous reports of splicing regulation of vesicle transport[73], also during differentiation processes[74]. A second group of terms related to signalling and cell communication also appears highly regulated by DIU, which together suggest high importance of AltTP in the response to extracellular signals, as recently reported[75]. This is particularly relevant to our system given that external stimuli are known to be involved in development[76] and require activation of

signaling pathways for an integrated differentiation response. In addition, the strong DIU regulation of terms such as *neuron projection* (Supplementary Figure 3), *plasma membrane* and *cell periphery* (Figure 3D) is in agreement with the established role of cell polarity and shape for NSC differentiation towards oligodendrocytes and the successful establishment of the myelin sheath[70]. Moreover, analysis of neural specific terms revealed that, while the regulatory terms (involving neuron survival and neurogenesis regulation) are mainly DE-regulated, the underlying differentiation processes (neurogenesis and neuron differentiation-related processes) predominantly involve DIU genes (Supplementary Figure 3). This suggests a transcriptional control of differentiation regulators that trigger differentiation processes that are in turn mostly AltTP-mediated. These results therefore point towards a strong interplay between gene expression and AltTP regulation, where the synergies between both, as well as each individual effects, are the ultimate drivers of biological processes that are key to neural development.

Finally, to deepen into the cellular functionalities solely regulated by AltTP, we used tappAS to calculate enrichment of DIU and DCU genes using the set of DE genes as background. As well as targets of several RNA binding proteins, we found significant enrichment of processes involved in 3'-end mRNA processing, RNA binding and mRNA splicing (Figure 3D), pointing towards a high degree of self-regulation of the post-transcriptional machinery in our system. Indeed, genes from several splicing regulator families, such as Ser/Arg-rich splicing factors (*Srsf5, Srsf10*), Muscleblind-like proteins (*Mbnl1, Mbnl2*) and RNA-binding motif proteins (*Rbm5, Rmb7*) undergo significant differential isoform/protein usage in our system (Supplementary Figure 4,

Supplementary Figure 6A). Additionally, the analysis indicated enrichment of DCU genes for cellular components and processes associated to neural development, such as neurite/axon outgrowth (*growth cone,* FDR=0.002; *site of polarized growth*, FDR=0.001)(Figure 3E), showing that the analysis of protein isoform changes may reveal interesting processes that remain hidden when solely looking at transcript usage. Moreover, significant enrichment was found for NLSs (FDR=0.02), indicating that differential coding sequence usage may change the subcellular localization of the resulting protein, and several PTMs (Phosphoserine, FDR=0.02; Phosphothreonine, FDR=0.02; Acetyl-Lysine, FDR=0.05), suggesting that AltTP may be related to post-translational modulation of protein function.

In conclusion, combining tappAS Differential and Enrichment modules allows disentangling the contribution of transcriptional and post-transcriptional regulation to transcriptome changes. In our proof of concept experimental system, both mechanisms affect to shared and specific processes jointly shaping the cell type differences.



Figure 3: Combined analysis of differential gene expression and AltTP in tappAS. A) UpSet plot showing intersections of DE vs DIU (left) and DIU vs DCU results, with and without minor isoform filtering. Horizontal bars correspond to the total set of genes detected as significantly DE or DIU. Matrix

points indicate the evaluated intersection, and vertical bars indicate their size. Legends detail the biological importance of each intersecting set of genes. B) From left to right, gene, transcript and protein-level expression charts for the *Rbm7* gene in our system, and tappAS graphical representation of its protein-level annotation. While there are no changes in gene expression level (not DE), the gene presents both differential isoform and coding sequence usage. C) Total usage change (i.e. expression redistribution between isoforms) vs log-transformed values of gene expression fold change between cell types. Genes with a major isoform switch are represented in orange. Labels are assigned to genes with the highest total usage change, indicating also whether they undergo major isoform switching. D) Multi-Dimensional Gene Set Enrichment Analysis of genes ranked by DE and DIU p.value. Nodes correspond to GO-terms obtained by selecting the top-25 terms ranked by significance in the DE enrichment and the top-25 terms ranked by significance in the DIU enrichment. Pie chart area represents DE and DIU regulation, and corresponds to relative -log10(p-value). E) and F) Functional Enrichment of DIU (E) and DCU (F) genes (Fisher´s Exact Test, with Benjamini-Hochberg multiple testing correction, minor isoform filtering: proportion < 10%) using DE genes as background. Dot color indicates the functional category of the feature, while dot size indicates significance.

Feature-level Analysis of AltTP and Differential Isoform Usage

To investigate how functional features are included/excluded due to differential usage of isoforms and AltTP, we applied tappAS' Differential Feature Inclusion (DFI) analysis. Differentially included features between NPC and OPC were identified in 526 genes, including ~83% of previously detected DIU genes, indicating that our framework recapitulates post-transcriptional regulation with changes in the functional properties of transcripts and proteins. Features positive for DFI were found distributed along all considered categories (Figure 4A), although a significant relative enrichment was found for uORFs (Fisher's exact test (FET) p-value=5.25e-121), RNA binding protein (RBP) binding sites (FET p-value=2.46e-07), compositional bias regions (FET p-value=4.06e-03) and IDRs (FET p-value 5.02e-03). Gene level DFI also

indicated IDRs and 5'UTR elements (particularly uORFs) as significantly differentially included (Figure 4B).

Moreover, we found feature gain to be more frequent in OPCs when compared to NPCs (Figure 4C), which can be interpreted as AltTP promoting the incorporation of functional properties as cells differentiate. For example, we observed OPC-specific inclusion of signal peptides (Binomial test, probability of success = 0.5, BiTest FDR = 2.10e-02), as well as of miRNA binding sites (BiTest FDR = 3.85e-08), uORFs (BiTest FDR = 5.85e-31) and RBP binding sites (BiTest FDR = 4.09e-04), which may indicate a 3' UTR lengthening trend in OPCs vs NPCs. Remarkably, when comparing (absolute) differences in feature inclusion rates between the two cell types, we found them to amount no more than 20% for most categories, suggesting that in our system AltTP acts as mechanism for the functional fine-tuning of gene products. Nevertheless, we found significant differences in feature total change (ΔFI, see Methods) across functional categories, being coiled regions and IDRs the protein domains with the highest change in inclusion levels between cell types (Figure 4D, Mann-Whitney test, disordered FDR = 3.63e-07, coiled FDR= 5.43e-06).



Figure 4: Summary of DFI results. A) Distribution (%) of features annotated in the transcriptome (dots) vs differentially included features revealed by the analysis (bars). The relative over-representation of DFI features in specific categories is evaluated by Fisher Exact tests and corrected for multiple testing using the Benjamini-Hochberg method. Significant categories are marked by asterisks (*). B) Distribution (%) of genes annotated for each feature category (dots) vs genes with differentially included features (bars). Significance (*): FET with Benjamini-Hochberg correction. C) Distribution (%) of differentially included

features according to the cell type in which the inclusion of the feature is favored. Categories enriched in cell type specific inclusion were captured using a Binomial test with probability = 0.5 and Benjamini-Hochberg multiple-testing correction. D) Differences in inclusion levels for each feature category across cell types measured by feature total change (ΔFI). Differential distribution across categories tested with the non-parametric Kruskal test. Significance scale: (***) $p < 0.001$; (**) $p < 0.01$; (*) $p < 0.05$. E) Top 15 co-DFI associations ranked by total genes with both features marked as DFI. Bar color indicates the number of genes where features are co-included in the same conditions (co-inclusion) or in opposite conditions/groups (mutual exclusion). F) Summary of features found to be significantly DFI using different comparison strategies.

In total, 526 genes were significant for DFI analysis, and many of these differentially included features related to binding properties and cellular localization. For example, we found a significant number of genes with isoforms differentially including Nuclear Localization Signals (n = 89), possibly regulating their switch between nucleus and cytosol as cell differentiate. This is the case of the *Ctnnd1* gene encoding p120, a well-known component of the ß-catenin signaling pathway, an important process in the differentiation of NPCs to OPCs[77,78]. tappAS predicted that *Ctnnd1* possesses an NLS motif in two of its alternative transcripts that appears due to exclusion of exon 10 (Figure 5A). We found *Ctnnd1* NLS-containing isoforms to be strongly downregulated in NPCs, while an isoform switching event leads to a significant increase in their expression levels in OPCs. Western blot analysis of *Ctnnd1* confirmed a localization change in OPCs and the increase of nuclear levels of the protein, while a cytoplasmic retention was observed in NPCs (Figure 5D). Similarly, tappAS found differential expression for the NLS of RBP *Mbnl1*, an important neural splicing factor. tappAS analysis indicates that nuclear MBNL1 isoforms are significantly favored in

NPCs with respect to OPCs (DIU p-value = 0.0018; Supplementary Figures 5A-C), and Western blot analyses confirmed these observations (Supplementary Figure 5D). Finally, tappAS also detected examples of DFI affecting binding properties. Isoforms of DNA-binding protein *Mbd1* showed differential inclusion of a non-constitutive zinc finger domain (Supplementary Figure 6A), favored as differentiation progresses (Supplementary Figure 6B), and further examination suggests a potential dual mechanism that involves both differential inclusion of exon 11 in OPCs and global upregulation of *Mbd1* gene expression (Supplementary Figure 6C). In agreement, post-transcriptional processing of *Mbd1* regulating the inclusion of exon 11 zinc finger domain was recently found to be an important determinant of cell lineage in NPCs[79].



Figure 5: tappAS analysis results and experimental validation AltTP processing of *Ctnnd1*. A) Protein-level visualization of tappAS functional annotation for *Ctnnd1*. Exclusion of an exon causes an NLS motif to appear in the sequence. B) Gene, transcript and CDS-level expression of *Ctnnd1*. The gene is significant for both DIU and DCU, with major isoform switching of the nuclear isoforms (yellow and red) in OPCs. C) DFI analysis results for the NLS motif in *Ctnnd1*. NLS inclusion is favored in OPCs. D) Western blot analysis of *Ctnnd1* in the nuclear and cytosolic fractions of NPCs and OPCs. An increase of the nuclear expression of the protein is observed in OPCs due to differential inclusion of the NLS, while cytosolic expression remains constant.

Another interesting functionality of tappAS is the ability to investigate the coordinated inclusion of functional features, by co-DFI analysis (Figure 4E). Results revealed associations between NLS and phosphoserine residues (examples in Supplementary Figure 7A and 7B) and C2H2-type zinc finger domains (examples in Supplementary Figures 7C and 7D). Indeed, post-translational masking of NLS is a known mechanism to prevent nuclear import[80,81]. Interestingly, IDRs are also strongly co-included with phosphoserine residues, confirming their described role in the allocation of PTMs, as well as their clear association to alternatively-spliced regions (examples in Supplementary Figure 7A and 7B).

Differential Polyadenylation

Alternative polyadenylation and differences at UTR lengths are involved in the regulation of mRNA stability, sub-cellular location, RNA protein binding and translation efficiency[82,83]. To assess the contribution of AltTP to these processes, tappAS implements Differential PolyAdenylation (DPA) and 3'UTR Lengthening (3UL) analyses (Table 1).

Applied to our experimental system, tappAS found that 17% of genes with polyA site variation across isoforms were positive for DPA (134 out of 1527, FDR < 0.001), among which ~31% (32 genes) switched their major polyA site between cell types (Figure 6A). A 56% of genes favored distal polyA site usage (DPAU) in OPCs and a significant trend towards 3' UTR lengthening was present for OPCs (Figure 6B, Wilcoxon signed rank test, p-value = 2.267e-05). These results are consistent with our enrichment analysis (Figure 4C). Moreover, 51 genes undergoing APA regulation also

had differential inclusion of miRNA binding motifs, with ~64% of DFI miRNA sites being included in OPCs. tappAS functional annotation indicated that an important number of these genes were involved in RNA processes, including *Papola*, *Tardbp* and *Tdrd3,* a transcriptional activator in the nucleus that is also involved in the formation of stress granules and the regulation of mRNA translation in the cytoplasm[84]. *Tdrd3* undergoes Coding Region APA, resulting in OPC upregulated forms with simultaneous inclusion of miRNAs binding sites and AU-Rich elements (ARE) at the 3'UTR (Figure 6C) and disruption of a phosphotyrosine site and an exon-junction (EJC) interacting region (Figure 6C) at the coding region. This pattern of functional regulation poses new hypothesis for the *Tdrd3* regulation by AltTP.



Figure 6: DPA results. A) Heatmap displaying DPAU levels associated to genes that are significantly DPA (FDR < 0.05) for each cell type. B) Boxplots showing the distribution of the difference in expression-weighted 3' and 5' UTR lengths (UTRw) in OPCs vs NPCs. C) tappAS visualization of transcript-level

annotation for the *Tdrd3* gene, where Codign Region -APA induced inclusion of several miRNA binding sites as well as an AU-rich element can be observed. D) *Tdrd3* protein-level annotation, EJC binding motif variation region is squared.

Discussion

In this work we present a novel analysis framework, implemented in the tappAS software, for the comprehensive functional analysis of isoform-resolved transcriptomes, referred here as Functional Iso-Transcriptomics (FIT). tappAS includes approaches for the analysis of the variability in functional sites at genes with multiple expressed transcripts, as well as methods to evaluate the functional impact of the context-dependent expression of alternative isoforms, and in particular to dissect which functional elements change as a consequence of differential isoform usage. We combine new analytical concepts such as FDA, DFI and U3L with more established enrichment methods to create a powerful analytical framework. This is a timely development at a moment when long-read technologies are becoming increasingly accessible, providing more accurate measurements of full-length transcripts and hence of isoform expression. However, we should highlight that tappAS is agnostic to the source of transcript models and therefore can also leverage other recently proposed strategies to improve accuracy at transcript calls such as the combination of ChIP-seq and RNA-seq data[85] and the pre-filtering of reference isoforms based on Event Analysis[86]. Given the pace of technology, we expect that full transcript resolution and quantification will be possible in the near future. While many methods to statistically evaluate isoform expression differences do exist[5–8], a tool specifically tailored to extract the functional readout of these isoform differences was missing,

and hence tappAS comes to fill an important bioinformatics gap for the study of AltTP biology.

tappAS is designed to be a flexible framework for functional analysis of isoforms, that uses an annotation file and many options for data analysis. At present tappAS includes pre-computed gff3 files for human, mouse, fly, arabidopsis and maize. In this work we illustrate the tool with the characterization of isoform differences between two mouse neural cell types. We show that tappAS recapitulates much of the existing knowledge about this neural system, as well as of functional aspects of splicing and UTR regulation. Moreover, we show that the tappAS framework is able to propose novel functional hypothesis that can be experimentally validated, such as the alternative inclusion of NLS in proteins regulated by splicing. However, the illustrating analysis, although comprehensive, does not cover all the tappAS potentiality. Options for specifying specific sets of genes or combining multiple functional layers are available, creating endless possibilities to interrogate the data. Video tutorials at the tappAS web site (tappas.org) showcase additional functionalities of this tool. Also, as gff3 can be directly uploaded by the user, additional data could be incorporate to allow for new questions. For example, at present, no Protein-Protein interaction data or conservation scores are included in the tappAS files. Users with confident annotations at these layers can update gff3 files and easily use the tappAS framework to pose questions regarding their association with isoforms and interactions with other functional layers. Similarly, as the tool is not limited by organism, but only by the current availability of annotation, other species not yet supported in the application will benefit from tappAS as functional information becomes available.

Acknowledgements

This work has been funded by Spanish Ministry of Education grant FPU2013/02348, Spanish MINECO BIO2015-1658-R and University of Florida Start up funds. We thank Dr. Manuel Tardáguila for assisting experimental validations and for valuable discussions on interpretation of results.

Author contributions

LdF: Major developer of analysis methods, analyzed data, interpreted results, contributed to software implementation and testing.

AA: Created manuscript draft and validated tappAS application.

MT: Developed analysis methods, performed validation experiments and contributed to interpretation.

HdR: Major software engineer of tappAS application.

MCM: Carried out experimental procedures and validation experiments.

ST: Contributed to statistical methods development.

PS: Contributed to software implementations.

RS: Contributed to validation experiments.

AAV: Performed cell culture experiments.

PB: Contributed to validation experiments.

JRBN: Contributed to drosophila isoform annotations.

LMM: Contributed to statistical methods development and manuscript writing.

VMM: Supervised experimental work, contributed to validation of results and data interpretation.

AC. Conceived the study, supervised experimental and analytical approaches and completed manuscript draft.

References

1. Stamm, S. *et al.* Function of alternative splicing. *Gene* (2005). doi:10.1016/j.gene.2004.10.022
2. Kelemen, O. *et al.* Function of alternative splicing. *Gene* **514**, 1–30 (2013).
3. Wang, E. T. *et al.* Alternative isoform regulation in human tissue transcriptomes. *Nature* **456**, 470–476 (2008).
4. Pan, Q., Shai, O., Lee, L. J., Frey, B. J. & Blencowe, B. J. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. *Nat. Genet.* **40**, 1413–1415 (2008).
5. Katz, Y., Wang, E. T., Airoldi, E. M. & Burge, C. B. Analysis and design of RNA sequencing experiments for identifying isoform regulation. *Nat. Methods* **7**, 1009–1015 (2010).
6. Anders, S., Reyes, A. & Huber, W. Detecting differential usage of exons from RNA-seq data. *Genome Res.* **22**, 2008–2017 (2012).
7. Shen, S. *et al.* rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-Seq data. *Proc. Natl. Acad. Sci. U. S. A.* **111**, E5593-601 (2014).
8. Trincado, J. L. *et al.* SUPPA2: Fast, accurate, and uncertainty-aware differential splicing analysis across multiple conditions. *Genome Biol.* **19**, (2018).
9. Yee, B. A., Pratt, G. A., Graveley, B. R., van Nostrand, E. L. & Yeo, G. W. RBP-Maps enables robust generation of splicing regulatory maps. *RNA* (2019). doi:10.1261/rna.069237.118
10. Witten, J. T. & Ule, J. Understanding splicing regulation through RNA splicing maps. *Trends in Genetics* **27**, 89–97 (2011).
11. Rot, G. *et al.* High-Resolution RNA Maps Suggest Common Principles of Splicing and Polyadenylation Regulation by TDP-43. *Cell Rep.* (2017). doi:10.1016/j.celrep.2017.04.028
12. Zheng, D. *et al.* Cellular stress alters 3'UTR landscape through alternative polyadenylation and isoform-specific degradation. *Nat. Commun.* (2018). doi:10.1038/s41467-018-04730-7
13. Weyn-Vanhentenryck, S. M. *et al.* Precise temporal regulation of alternative splicing during neural development. *Nat. Commun.* (2018). doi:10.1038/s41467-018-04559-0
14. Han, H. *et al.* MBNL proteins repress ES-cell-specific alternative splicing and reprogramming. *Nature* **498**, 241–245 (2013).
15. Sulakhe, D. *et al.* Exploring the functional impact of alternative splicing on human protein isoforms using available annotation sources. *Brief. Bioinform.* (2018). doi:10.1093/bib/bby047
16. Tress, M. L., Abascal, F. & Valencia, A. Most Alternative Isoforms Are Not Functionally Important. *Trends Biochem. Sci.* **42**, 408–410 (2017).
17. Tress, M. L., Abascal, F. & Valencia, A. Alternative Splicing May Not Be the Key to Proteome Complexity. *Trends Biochem. Sci.* **42**, 98–110 (2017).
18. Furlanis, E. & Scheiffele, P. Regulation of Neuronal Differentiation, Function, and Plasticity by Alternative Splicing. *Annu. Rev. Cell Dev. Biol.* **34**, 451–469 (2018).
19. Sen, S., Jumaa, H. & Webster, N. J. G. Splicing factor SRSF3 is crucial for hepatocyte differentiation and metabolic function. *Nat. Commun.* **4**, 1336 (2013).
20. Li, H. *et al.* SRSF10 Regulates Alternative Splicing and Is Required for Adipocyte Differentiation. *Mol. Cell. Biol.* **34**, 2198–2207 (2014).
21. Ke, S. & Chasin, L. A. Context-dependent splicing regulation: Exon definition, co-occurring motif pairs and tissue specificity. *RNA Biol.* **8**, 384–388 (2011).
22. Saha, A. *et al.* Co-expression networks reveal the tissue-specific regulation of transcription and splicing. *Genome Res.* **27**, 1843–1858 (2017).
23. Baralle, F. E. & Giudice, J. Alternative splicing as a regulator of development and tissue identity. *Nature Reviews Molecular Cell Biology* (2017). doi:10.1038/nrm.2017.27
24. Pleiss, J. A., Whitworth, G. B., Bergkessel, M. & Guthrie, C. Rapid, Transcript-Specific Changes in Splicing in Response to Environmental Stress. *Mol. Cell* (2007). doi:10.1016/j.molcel.2007.07.018
25. Paronetto, M. P., Passacantilli, I. & Sette, C. Alternative splicing and cell survival: from tissue homeostasis to disease. *Cell Death Differ.* **23**, 1919–1929 (2016).
26. Scotti, M. M. & Swanson, M. S. RNA mis-splicing in disease. *Nature Reviews Genetics* (2016). doi:10.1038/nrg.2015.3
27. Cieply, B. & Carstens, R. P. Functional roles of alternative splicing factors in human disease. *Wiley Interdisciplinary Reviews: RNA* (2015). doi:10.1002/wrna.1276
28. Daguenet, E., Dujardin, G. & Valcarcel, J. The pathogenicity of splicing defects: mechanistic insights into pre-mRNA processing inform novel therapeutic approaches. *EMBO Rep.* **16**, 1640–

1655 (2015).
29. Buljan, M. *et al.* Tissue-Specific Splicing of Disordered Segments that Embed Binding Motifs Rewires Protein Interaction Networks. *Mol. Cell* (2012). doi:10.1016/j.molcel.2012.05.039
30. Yang, X. *et al.* Widespread Expansion of Protein Interaction Capabilities by Alternative Splicing. *Cell* **164**, 805–817 (2016).
31. Ellis, J. D. *et al.* Tissue-Specific Alternative Splicing Remodels Protein-Protein Interaction Networks. *Mol. Cell* (2012). doi:10.1016/j.molcel.2012.05.037
32. Climente-González, H., Porta-Pardo, E., Godzik, A. & Eyras, E. The Functional Impact of Alternative Splicing in Cancer. *Cell Rep.* **20**, 2215–2226 (2017).
33. Hoffman, Y. *et al.* 3'UTR Shortening Potentiates MicroRNA-Based Repression of Pro-differentiation Genes in Proliferating Human Cells. *PLoS Genet.* (2016). doi:10.1371/journal.pgen.1005879
34. Fu, Y. *et al.* Crosstalk between alternative polyadenylation and miRNAs in the regulation of protein translational efficiency. *Genome Res.* (2018). doi:10.1101/gr.231506.117
35. Kurihara, Y. *et al.* Transcripts from downstream alternative transcription start sites evade uORF-mediated inhibition of gene expression in Arabidopsis . *Proc. Natl. Acad. Sci.* (2018). doi:10.1073/pnas.1804971115
36. Whiffin, N. *et al.* Characterising the loss-of-function impact of 5' untranslated region variants in whole genome sequence data from 15,708 individuals. *bioRxiv* 543504 (2019). doi:10.1101/543504
37. Wang, X., Hou, J., Quedenau, C. & Chen, W. Pervasive isoform-specific translational regulation via alternative transcription start sites in mammals. *Mol. Syst. Biol.* (2016). doi:10.15252/msb.20166941
38. Jaffrey, S. R. & Wilkinson, M. F. Nonsense-mediated RNA decay in the brain: emerging modulator of neural development and disease. *Nature Reviews Neuroscience* (2018). doi:10.1038/s41583-018-0079-z
39. Zheng, S. Alternative splicing and nonsense-mediated mRNA decay enforce neural specific gene expression. *International Journal of Developmental Neuroscience* (2016). doi:10.1016/j.ijdevneu.2016.03.003
40. Huang, D. W. *et al.* The DAVID Gene Functional Classification Tool: A novel biological module-centric algorithm to functionally analyze large gene lists. *Genome Biol.* **8**, (2007).
41. Medina, I. *et al.* Babelomics: An integrative platform for the analysis of transcriptomics, proteomics and genomic data with advanced functional profiling. *Nucleic Acids Res.* **38**, (2010).
42. Mootha, V. K. *et al.* PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nat. Genet.* **34**, 267–273 (2003).
43. Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 15545–50 (2005).
44. Wong, J. J. L. *et al.* Orchestrated intron retention regulates normal granulocyte differentiation. *Cell* (2013). doi:10.1016/j.cell.2013.06.052
45. Elkon, R., Ugalde, A. P. & Agami, R. Alternative cleavage and polyadenylation: Extent, regulation and function. *Nature Reviews Genetics* **14**, 496–506 (2013).
46. Xia, Z. *et al.* Dynamic analyses of alternative polyadenylation from RNA-seq reveal a 3'2-UTR landscape across seven tumour types. *Nat. Commun.* (2014). doi:10.1038/ncomms6274
47. Irimia, M. *et al.* A highly conserved program of neuronal microexons is misregulated in autistic brains. *Cell* (2014). doi:10.1016/j.cell.2014.11.035
48. Hatje, K. *et al.* The landscape of human mutually exclusive splicing. *Mol. Syst. Biol.* (2017). doi:10.15252/msb.20177728
49. Braunschweig, U., Gueroussov, S., Plocik, A. M., Graveley, B. R. & Blencowe, B. J. Dynamic integration of splicing within gene regulatory pathways. *Cell* **152**, 1252–1269 (2013).
50. Tranchevent, L. C. *et al.* Identification of protein features encoded by alternative exons using Exon Ontology. *Genome Res.* **27**, 1087–1097 (2017).
51. Steijger, T., Abril, J. F., Engström, P. G. & Kokocinski, F. Europe PMC Funders Group Assessment of transcript reconstruction methods for RNA-seq. **10**, 1–20 (2014).
52. Wang, B. *et al.* Unveiling the complexity of the maize transcriptome by single-molecule long-read sequencing. *Nat. Commun.* **7**, (2016).
53. Sahlin, K., Tomaszkiewicz, M., Makova, K. D. & Medvedev, P. Deciphering highly similar multigene family transcripts from Iso-Seq data with IsoCon. *Nat. Commun.* **9**, (2018).

54. Kuo, R. I. *et al.* Normalized long read RNA sequencing in chicken reveals transcriptome complexity similar to human. *BMC Genomics* (2017). doi:10.1186/s12864-017-3691-9
55. Weirather, J. L. *et al.* Comprehensive comparison of Pacific Biosciences and Oxford Nanopore Technologies and their applications to transcriptome analysis. *F1000Research* **6**, 100 (2017).
56. Chao, Y. *et al.* Analysis of transcripts and splice isoforms in red clover (Trifolium pratense L.) by single-molecule long-read sequencing. *BMC Plant Biol.* (2018). doi:10.1186/s12870-018-1534-8
57. Tardaguila, M. *et al.* SQANTI: extensive characterization of long-read transcript sequences for quality control in full-length transcriptome identification and quantification. *Genome Res.* (2018). doi:10.1101/gr.222976.117
58. Young, M. D., Wakefield, M. J., Smyth, G. K. & Oshlack, A. Gene ontology analysis for RNA-seq: accounting for selection bias. *Genome Biol.* **11**, R14 (2010).
59. Mi, G., Di, Y., Emerson, S., Cumbie, J. S. & Chang, J. H. Length Bias Correction in Gene Ontology Enrichment Analysis Using Logistic Regression. *PLoS One* **7**, e46128 (2012).
60. Lykke-Andersen, S. & Jensen, T. H. Nonsense-mediated mRNA decay: An intricate machinery that shapes transcriptomes. *Nature Reviews Molecular Cell Biology* **16**, 665–677 (2015).
61. Vlasova, I. A. *et al.* Conserved GU-Rich Elements Mediate mRNA Decay by Binding to CUG-Binding Protein 1. *Mol. Cell* **29**, 263–270 (2008).
62. Vlasova, I. A. & Bohjanen, P. R. Posttranscriptional regulation of gene networks by GU-rich elements and CELF proteins. *RNA Biology* **5**, 201–207 (2008).
63. Tarn, W.-Y. *et al.* RBM4 promotes neuronal differentiation and neurite outgrowth by modulating Numb isoform expression. *Mol. Biol. Cell* **27**, 1676–1683 (2016).
64. Uittenbogaard, M. & Chiaramello, A. Expression of the bHLH transcription factor Tcf12 (ME1) gene is linked to the expansion of precursor cell populations during neurogenesis. *Brain Res. Gene Expr. Patterns* (2002).
65. Birch, D., Britt, B. C., Dukes, S. C., Kessler, J. A. & Dizon, M. L. V. MicroRNAs participate in the murine oligodendroglial response to perinatal hypoxia-ischemia. *Pediatr. Res.* **76**, 334–340 (2014).
66. Dong, Y. & Qiu, G.-B. Biological functions of miR-590 and its role in carcinogenesis. *Front. Lab. Med.* **1**, 173–176 (2017).
67. Romero, P. R. *et al.* Alternative splicing in concert with protein intrinsic disorder enables increased functional diversity in multicellular organisms. *Proc. Natl. Acad. Sci.* **103**, 8390–8395 (2006).
68. Colak, R. *et al.* Distinct Types of Disorder in the Human Proteome: Functional Implications for Alternative Splicing. *PLoS Comput. Biol.* (2013). doi:10.1371/journal.pcbi.1003030
69. Montaner, D. & Dopazo, J. Multidimensional gene set analysis of genomic data. *PLoS One* **5**, 103–48 (2010).
70. Maier, O., Hoekstra, D. & Baron, W. Polarity development in oligodendrocytes: Sorting and trafficking of myelin components. *Journal of Molecular Neuroscience* **35**, 35–53 (2008).
71. Krämer, E. M., Schardt, A. & Nave, K. A. Membrane traffic in myelinating oligodendrocytes. *Microsc. Res. Tech.* **52**, 656–671 (2001).
72. Baron, W. & Hoekstra, D. On the biogenesis of myelin membranes: Sorting, trafficking and cell polarity. *FEBS Letters* (2010). doi:10.1016/j.febslet.2009.10.085
73. Blue, R. E., Curry, E. G., Engels, N. M., Lee, E. Y. & Giudice, J. How alternative splicing affects membrane-trafficking dynamics. *J. Cell Sci.* (2018). doi:10.1242/jcs.216465
74. Giudice, J. *et al.* Alternative splicing regulates vesicular trafficking genes in cardiomyocytes during postnatal heart development. *Nat. Commun.* **5**, (2014).
75. Wright, P. E. & Dyson, H. J. Intrinsically disordered proteins in cellular signalling and regulation. *Nat. Rev. Mol. Cell Biol.* **16**, 18–29 (2015).
76. Ma, W. *et al.* Cell-extracellular matrix interactions regulate neural differentiation of human embryonic stem cells. *BMC Dev. Biol.* **8**, 90 (2008).
77. Elia, L. P., Yamamoto, M., Zang, K. & Reichardt, L. F. p120 Catenin Regulates Dendritic Spine and Synapse Development through Rho-Family GTPases and Cadherins. *Neuron* **51**, 43–56 (2006).
78. Munji, R. N., Choe, Y., Li, G., Siegenthaler, J. A. & Pleasure, S. J. Wnt Signaling Regulates Neuronal Differentiation of Cortical Intermediate Progenitors. *J. Neurosci.* **31**, 1676–1687 (2011).
79. Jobe, E. M. *et al.* Methyl-CpG-Binding Protein MBD1 Regulates Neuronal Lineage Commitment through Maintaining Adult Neural Stem Cell Identity. *J. Neurosci.* **37**, 523–536 (2017).
80. Harreman, M. T. *et al.* Regulation of nuclear import by phosphorylation adjacent to nuclear localization signals. *J. Biol. Chem.* **279**, 20613–20621 (2004).

81. Nardozzi, J. D., Lott, K. & Cingolani, G. Phosphorylation meets nuclear import: A review. *Cell Communication and Signaling* (2010). doi:10.1186/1478-811X-8-32
82. Elkon, R., Ugalde, A. P. & Agami, R. Alternative cleavage and polyadenylation: Extent, regulation and function. *Nature Reviews Genetics* (2013). doi:10.1038/nrg3482
83. Tian, B. & Manley, J. L. Alternative polyadenylation of mRNA precursors. *Nat. Rev. Mol. Cell Biol.* **18**, 18–30 (2016).
84. Goulet, I., Boisvenue, S., Mokas, S., Mazroui, R. & Côté, J. TDRD3, a novel Tudor domain-containing protein, localizes to cytoplasmic stress granules. *Hum. Mol. Genet.* **17**, 3055–3074 (2008).
85. Liu, P., Sanalkumar, R., Bresnick, E. H., Keleş, S. & Dewey, C. N. Integrative analysis with ChIP-seq advances the limits of transcript quantification from RNA-seq. *Genome Res.* **26**, 1124–1133 (2016).
86. Newman, J. R. B., Concannon, P., Tardaguila, M., Conesa, A. & McIntyre, L. M. Event Analysis: Using Transcript Events To Improve Estimates of Abundance in RNA-seq Data. *G3:Genes|Genomes|Genetics* **8**, 2923–2940 (2018).
87. Grillo, G. *et al.* UTRdb and UTRsite (RELEASE 2010): A collection of sequences and regulatory motifs of the untranslated regions of eukaryotic mRNAs. *Nucleic Acids Res.* (2009). doi:10.1093/nar/gkp902
88. Tempel, S. Using and understanding repeatMasker. *Methods Mol. Biol.* **859**, 29–51 (2012).
89. Dweep, H. & Gretz, N. miRWalk2.0: a comprehensive atlas of microRNA-target interactions. *Nat. Methods* **12**, 697–697 (2015).
90. Agarwal, V., Bell, G. W., Nam, J.-W. & Bartel, D. P. Predicting effective microRNA target sites in mammalian mRNAs. *Elife* **4**, (2015).
91. Enright, A. J. *et al.* MicroRNA targets in Drosophila. *Genome Biol.* **5**, R1 (2003).
92. Kozomara, A. & Griffiths-Jones, S. MiRBase: Annotating high confidence microRNAs using deep sequencing data. *Nucleic Acids Res.* **42**, (2014).
93. Yang, Y. C. T. *et al.* CLIPdb: A CLIP-seq database for protein-RNA interactions. *BMC Genomics* **16**, (2015).
94. Quevillon, E. *et al.* InterProScan: Protein domains identifier. *Nucleic Acids Res.* **33**, (2005).
95. Krogh, A., Larsson, B., Von Heijne, G. & Sonnhammer, E. L. L. Predicting transmembrane protein topology with a hidden Markov model: Application to complete genomes. *J. Mol. Biol.* **305**, 567–580 (2001).
96. Petersen, T. N., Brunak, S., von Heijne, G. & Nielsen, H. SignalP 4.0: discriminating signal peptides from transmembrane regions. *Nat. Methods* **8**, 785–786 (2011).
97. Lupas, A., Van Dyke, M. & Stock, J. Predicting coiled coils from protein sequences. *Science (80-.).* **252**, 1162–1164 (1991).
98. Kosugi, S., Hasebe, M., Tomita, M. & Yanagawa, H. Systematic identification of cell cycle-dependent yeast nucleocytoplasmic shuttling proteins by prediction of composite motifs. *Proc. Natl. Acad. Sci.* **106**, 10171–10176 (2009).
99. Necci, M., Piovesan, D., Dosztanyi, Z. & Tosatto, S. C. E. MobiDB-lite: Fast and highly specific consensus prediction of intrinsic disorder in proteins. *Bioinformatics* **33**, 1402–1404 (2017).
100. Zhang, Z. *et al.* Noisy splicing, more than expression regulation, explains why some exons are subject to nonsense-mediated mRNA decay. *BMC Biol.* **7**, (2009).
101. UniProt Consortium, T. U. The Universal Protein Resource (UniProt). *Nucleic Acids Res.* (2007). doi:10.1093/nar/gkl929
102. Hornbeck, P. V. *et al.* PhosphoSitePlus, 2014: Mutations, PTMs and recalibrations. *Nucleic Acids Res.* **43**, D512–D520 (2015).
103. Pauws, E. Heterogeneity in polyadenylation cleavage sites in mammalian mRNA sequences: implications for SAGE analysis. *Nucleic Acids Res.* **29**, 1690–1694 (2001).
104. Fisher, R. A. On the Interpretation of χ 2 from Contingency Tables, and the Calculation of P. *J. R. Stat. Soc.* **85**, 87–94 (1922).
105. Benjamini, Yoav ; Hochberg, Y. Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B-Methodological 1995.pdf. *J. R. Stat. Soc. Ser. B* **57**, 289–300 (1995).
106. Nueda, M. J., Tarazona, S. & Conesa, A. Next maSigPro: Updating maSigPro bioconductor package for RNA-seq time series. *Bioinformatics* **30**, 2598–2602 (2014).
107. Ha, K. C. H., Blencowe, B. J. & Morris, Q. QAPA: A new method for the systematic analysis of alternative polyadenylation from RNA-seq data. *Genome Biol.* (2018). doi:10.1186/s13059-018-

1414-4
108. Tarazona, S. *et al.* Data quality aware analysis of differential expression in RNA-seq with NOISeq R/Bioc package. *Nucleic Acids Res.* **43**, (2015).
109. Nueda, M. J., Martorell-Marugan, J., Martí, C., Tarazona, S. & Conesa, A. Identification and visualization of differential isoform expression in RNA-seq time series. *Bioinformatics* **34**, 524–526 (2018).
110. McIntyre, L. M. *et al.* Sex-specific expression of alternative transcripts in Drosophila. *Genome Biol.* **7**, R79 (2006).
111. Gonzàlez-Porta, M., Frankish, A., Rung, J., Harrow, J. & Brazma, A. Transcriptome analysis of human tissues and cell lines reveals one dominant transcript per gene. *Genome Biol.* **14**, R70 (2013).
112. Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. *BMC Bioinformatics* **12**, 323 (2011).

2. Kelemen, O. *et al.* Function of alternative splicing. *Gene* **514**, 1–30 (2013).
3. Wang, E. T. *et al.* Alternative isoform regulation in human tissue transcriptomes. *Nature* **456**, 470–476 (2008).
4. Pan, Q., Shai, O., Lee, L. J., Frey, B. J. & Blencowe, B. J. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. *Nat. Genet.* **40**, 1413–1415 (2008).
5. Katz, Y., Wang, E. T., Airoldi, E. M. & Burge, C. B. Analysis and design of RNA sequencing experiments for identifying isoform regulation. *Nat. Methods* **7**, 1009–1015 (2010).
6. Anders, S., Reyes, A. & Huber, W. Detecting differential usage of exons from RNA-seq data. *Genome Res.* **22**, 2008–2017 (2012).
7. Shen, S. *et al.* rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-Seq data. *Proc. Natl. Acad. Sci. U. S. A.* **111**, E5593-601 (2014).
8. Trincado, J. L. *et al.* SUPPA2: Fast, accurate, and uncertainty-aware differential splicing analysis across multiple conditions. *Genome Biol.* **19**, (2018).
9. Yee, B. A., Pratt, G. A., Graveley, B. R., van Nostrand, E. L. & Yeo, G. W. RBP-Maps enables robust generation of splicing regulatory maps. *RNA* (2019). doi:10.1261/rna.069237.118
10. Witten, J. T. & Ule, J. Understanding splicing regulation through RNA splicing maps. *Trends in Genetics* **27**, 89–97 (2011).
11. Rot, G. *et al.* High-Resolution RNA Maps Suggest Common Principles of Splicing and Polyadenylation Regulation by TDP-43. *Cell Rep.* (2017). doi:10.1016/j.celrep.2017.04.028
12. Zheng, D. *et al.* Cellular stress alters 3'UTR landscape through alternative polyadenylation and isoform-specific degradation. *Nat. Commun.* (2018). doi:10.1038/s41467-018-04730-7
13. Weyn-Vanhentenryck, S. M. *et al.* Precise temporal regulation of alternative splicing during neural development. *Nat. Commun.* (2018). doi:10.1038/s41467-018-04559-0
14. Han, H. *et al.* MBNL proteins repress ES-cell-specific alternative splicing and reprogramming. *Nature* **498**, 241–245 (2013).
15. Sulakhe, D. *et al.* Exploring the functional impact of alternative splicing on human protein isoforms using available annotation sources. *Brief. Bioinform.* (2018). doi:10.1093/bib/bby047
16. Tress, M. L., Abascal, F. & Valencia, A. Most Alternative Isoforms Are Not Functionally Important. *Trends Biochem. Sci.* **42**, 408–410 (2017).
17. Tress, M. L., Abascal, F. & Valencia, A. Alternative Splicing May Not Be the Key to Proteome Complexity. *Trends Biochem. Sci.* **42**, 98–110 (2017).
18. Furlanis, E. & Scheiffele, P. Regulation of Neuronal Differentiation, Function, and Plasticity by Alternative Splicing. *Annu. Rev. Cell Dev. Biol.* **34**, 451–469 (2018).
19. Sen, S., Jumaa, H. & Webster, N. J. G. Splicing factor SRSF3 is crucial for hepatocyte differentiation and metabolic function. *Nat. Commun.* **4**, 1336 (2013).
20. Li, H. *et al.* SRSF10 Regulates Alternative Splicing and Is Required for Adipocyte Differentiation. *Mol. Cell. Biol.* **34**, 2198–2207 (2014).
21. Ke, S. & Chasin, L. A. Context-dependent splicing regulation: Exon definition, co-occurring motif pairs and tissue specificity. *RNA Biol.* **8**, 384–388 (2011).
22. Saha, A. *et al.* Co-expression networks reveal the tissue-specific regulation of transcription and splicing. *Genome Res.* **27**, 1843–1858 (2017).
23. Baralle, F. E. & Giudice, J. Alternative splicing as a regulator of development and tissue identity. *Nature Reviews Molecular Cell Biology* (2017). doi:10.1038/nrm.2017.27

24. Pleiss, J. A., Whitworth, G. B., Bergkessel, M. & Guthrie, C. Rapid, Transcript-Specific Changes in Splicing in Response to Environmental Stress. *Mol. Cell* (2007). doi:10.1016/j.molcel.2007.07.018
25. Paronetto, M. P., Passacantilli, I. & Sette, C. Alternative splicing and cell survival: from tissue homeostasis to disease. *Cell Death Differ.* **23**, 1919–1929 (2016).
26. Scotti, M. M. & Swanson, M. S. RNA mis-splicing in disease. *Nature Reviews Genetics* (2016). doi:10.1038/nrg.2015.3
27. Cieply, B. & Carstens, R. P. Functional roles of alternative splicing factors in human disease. *Wiley Interdisciplinary Reviews: RNA* (2015). doi:10.1002/wrna.1276
28. Daguenet, E., Dujardin, G. & Valcarcel, J. The pathogenicity of splicing defects: mechanistic insights into pre-mRNA processing inform novel therapeutic approaches. *EMBO Rep.* **16**, 1640–1655 (2015).
29. Buljan, M. *et al.* Tissue-Specific Splicing of Disordered Segments that Embed Binding Motifs Rewires Protein Interaction Networks. *Mol. Cell* (2012). doi:10.1016/j.molcel.2012.05.039
30. Yang, X. *et al.* Widespread Expansion of Protein Interaction Capabilities by Alternative Splicing. *Cell* **164**, 805–817 (2016).
31. Ellis, J. D. *et al.* Tissue-Specific Alternative Splicing Remodels Protein-Protein Interaction Networks. *Mol. Cell* (2012). doi:10.1016/j.molcel.2012.05.037
32. Climente-González, H., Porta-Pardo, E., Godzik, A. & Eyras, E. The Functional Impact of Alternative Splicing in Cancer. *Cell Rep.* **20**, 2215–2226 (2017).
33. Hoffman, Y. *et al.* 3'UTR Shortening Potentiates MicroRNA-Based Repression of Pro-differentiation Genes in Proliferating Human Cells. *PLoS Genet.* (2016). doi:10.1371/journal.pgen.1005879
34. Fu, Y. *et al.* Crosstalk between alternative polyadenylation and miRNAs in the regulation of protein translational efficiency. *Genome Res.* (2018). doi:10.1101/gr.231506.117
35. Kurihara, Y. *et al.* Transcripts from downstream alternative transcription start sites evade uORF-mediated inhibition of gene expression in Arabidopsis . *Proc. Natl. Acad. Sci.* (2018). doi:10.1073/pnas.1804971115
36. Whiffin, N. *et al.* Characterising the loss-of-function impact of 5' untranslated region variants in whole genome sequence data from 15,708 individuals. *bioRxiv* 543504 (2019). doi:10.1101/543504
37. Wang, X., Hou, J., Quedenau, C. & Chen, W. Pervasive isoform-specific translational regulation via alternative transcription start sites in mammals. *Mol. Syst. Biol.* (2016). doi:10.15252/msb.20166941
38. Jaffrey, S. R. & Wilkinson, M. F. Nonsense-mediated RNA decay in the brain: emerging modulator of neural development and disease. *Nature Reviews Neuroscience* (2018). doi:10.1038/s41583-018-0079-z
39. Zheng, S. Alternative splicing and nonsense-mediated mRNA decay enforce neural specific gene expression. *International Journal of Developmental Neuroscience* (2016). doi:10.1016/j.ijdevneu.2016.03.003
40. Huang, D. W. *et al.* The DAVID Gene Functional Classification Tool: A novel biological module-centric algorithm to functionally analyze large gene lists. *Genome Biol.* **8**, (2007).
41. Medina, I. *et al.* Babelomics: An integrative platform for the analysis of transcriptomics, proteomics and genomic data with advanced functional profiling. *Nucleic Acids Res.* **38**, (2010).
42. Mootha, V. K. *et al.* PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nat. Genet.* **34**, 267–273 (2003).
43. Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 15545–50 (2005).
44. Wong, J. J. L. *et al.* Orchestrated intron retention regulates normal granulocyte differentiation. *Cell* (2013). doi:10.1016/j.cell.2013.06.052
45. Elkon, R., Ugalde, A. P. & Agami, R. Alternative cleavage and polyadenylation: Extent, regulation and function. *Nature Reviews Genetics* **14**, 496–506 (2013).
46. Xia, Z. *et al.* Dynamic analyses of alternative polyadenylation from RNA-seq reveal a 3'2-UTR landscape across seven tumour types. *Nat. Commun.* (2014). doi:10.1038/ncomms6274
47. Irimia, M. *et al.* A highly conserved program of neuronal microexons is misregulated in autistic brains. *Cell* (2014). doi:10.1016/j.cell.2014.11.035
48. Hatje, K. *et al.* The landscape of human mutually exclusive splicing. *Mol. Syst. Biol.* (2017). doi:10.15252/msb.20177728

49. Braunschweig, U., Gueroussov, S., Plocik, A. M., Graveley, B. R. & Blencowe, B. J. Dynamic integration of splicing within gene regulatory pathways. *Cell* **152**, 1252–1269 (2013).
50. Tranchevent, L. C. *et al.* Identification of protein features encoded by alternative exons using Exon Ontology. *Genome Res.* **27**, 1087–1097 (2017).
51. Steijger, T., Abril, J. F., Engström, P. G. & Kokocinski, F. Europe PMC Funders Group Assessment of transcript reconstruction methods for RNA-seq. **10**, 1–20 (2014).
52. Wang, B. *et al.* Unveiling the complexity of the maize transcriptome by single-molecule long-read sequencing. *Nat. Commun.* **7**, (2016).
53. Sahlin, K., Tomaszkiewicz, M., Makova, K. D. & Medvedev, P. Deciphering highly similar multigene family transcripts from Iso-Seq data with IsoCon. *Nat. Commun.* **9**, (2018).
54. Kuo, R. I. *et al.* Normalized long read RNA sequencing in chicken reveals transcriptome complexity similar to human. *BMC Genomics* (2017). doi:10.1186/s12864-017-3691-9
55. Weirather, J. L. *et al.* Comprehensive comparison of Pacific Biosciences and Oxford Nanopore Technologies and their applications to transcriptome analysis. *F1000Research* **6**, 100 (2017).
56. Chao, Y. *et al.* Analysis of transcripts and splice isoforms in red clover (Trifolium pratense L.) by single-molecule long-read sequencing. *BMC Plant Biol.* (2018). doi:10.1186/s12870-018-1534-8
57. Tardaguila, M. *et al.* SQANTI: extensive characterization of long-read transcript sequences for quality control in full-length transcriptome identification and quantification. *Genome Res.* (2018). doi:10.1101/gr.222976.117
58. Young, M. D., Wakefield, M. J., Smyth, G. K. & Oshlack, A. Gene ontology analysis for RNA-seq: accounting for selection bias. *Genome Biol.* **11**, R14 (2010).
59. Mi, G., Di, Y., Emerson, S., Cumbie, J. S. & Chang, J. H. Length Bias Correction in Gene Ontology Enrichment Analysis Using Logistic Regression. *PLoS One* **7**, e46128 (2012).
60. Lykke-Andersen, S. & Jensen, T. H. Nonsense-mediated mRNA decay: An intricate machinery that shapes transcriptomes. *Nature Reviews Molecular Cell Biology* **16**, 665–677 (2015).
61. Vlasova, I. A. *et al.* Conserved GU-Rich Elements Mediate mRNA Decay by Binding to CUG-Binding Protein 1. *Mol. Cell* **29**, 263–270 (2008).
62. Vlasova, I. A. & Bohjanen, P. R. Posttranscriptional regulation of gene networks by GU-rich elements and CELF proteins. *RNA Biology* **5**, 201–207 (2008).
63. Tarn, W.-Y. *et al.* RBM4 promotes neuronal differentiation and neurite outgrowth by modulating Numb isoform expression. *Mol. Biol. Cell* **27**, 1676–1683 (2016).
64. Uittenbogaard, M. & Chiaramello, A. Expression of the bHLH transcription factor Tcf12 (ME1) gene is linked to the expansion of precursor cell populations during neurogenesis. *Brain Res. Gene Expr. Patterns* (2002).
65. Birch, D., Britt, B. C., Dukes, S. C., Kessler, J. A. & Dizon, M. L. V. MicroRNAs participate in the murine oligodendroglial response to perinatal hypoxia-ischemia. *Pediatr. Res.* **76**, 334–340 (2014).
66. Dong, Y. & Qiu, G.-B. Biological functions of miR-590 and its role in carcinogenesis. *Front. Lab. Med.* **1**, 173–176 (2017).
67. Romero, P. R. *et al.* Alternative splicing in concert with protein intrinsic disorder enables increased functional diversity in multicellular organisms. *Proc. Natl. Acad. Sci.* **103**, 8390–8395 (2006).
68. Colak, R. *et al.* Distinct Types of Disorder in the Human Proteome: Functional Implications for Alternative Splicing. *PLoS Comput. Biol.* (2013). doi:10.1371/journal.pcbi.1003030
69. Montaner, D. & Dopazo, J. Multidimensional gene set analysis of genomic data. *PLoS One* **5**, 103–48 (2010).
70. Maier, O., Hoekstra, D. & Baron, W. Polarity development in oligodendrocytes: Sorting and trafficking of myelin components. *Journal of Molecular Neuroscience* **35**, 35–53 (2008).
71. Krämer, E. M., Schardt, A. & Nave, K. A. Membrane traffic in myelinating oligodendrocytes. *Microsc. Res. Tech.* **52**, 656–671 (2001).
72. Baron, W. & Hoekstra, D. On the biogenesis of myelin membranes: Sorting, trafficking and cell polarity. *FEBS Letters* (2010). doi:10.1016/j.febslet.2009.10.085
73. Blue, R. E., Curry, E. G., Engels, N. M., Lee, E. Y. & Giudice, J. How alternative splicing affects membrane-trafficking dynamics. *J. Cell Sci.* (2018). doi:10.1242/jcs.216465
74. Giudice, J. *et al.* Alternative splicing regulates vesicular trafficking genes in cardiomyocytes during postnatal heart development. *Nat. Commun.* **5**, (2014).
75. Wright, P. E. & Dyson, H. J. Intrinsically disordered proteins in cellular signalling and regulation. *Nat. Rev. Mol. Cell Biol.* **16**, 18–29 (2015).

76. Ma, W. *et al.* Cell-extracellular matrix interactions regulate neural differentiation of human embryonic stem cells. *BMC Dev. Biol.* **8**, 90 (2008).
77. Elia, L. P., Yamamoto, M., Zang, K. & Reichardt, L. F. p120 Catenin Regulates Dendritic Spine and Synapse Development through Rho-Family GTPases and Cadherins. *Neuron* **51**, 43–56 (2006).
78. Munji, R. N., Choe, Y., Li, G., Siegenthaler, J. A. & Pleasure, S. J. Wnt Signaling Regulates Neuronal Differentiation of Cortical Intermediate Progenitors. *J. Neurosci.* **31**, 1676–1687 (2011).
79. Jobe, E. M. *et al.* Methyl-CpG-Binding Protein MBD1 Regulates Neuronal Lineage Commitment through Maintaining Adult Neural Stem Cell Identity. *J. Neurosci.* **37**, 523–536 (2017).
80. Harreman, M. T. *et al.* Regulation of nuclear import by phosphorylation adjacent to nuclear localization signals. *J. Biol. Chem.* **279**, 20613–20621 (2004).
81. Nardozzi, J. D., Lott, K. & Cingolani, G. Phosphorylation meets nuclear import: A review. *Cell Communication and Signaling* (2010). doi:10.1186/1478-811X-8-32
82. Elkon, R., Ugalde, A. P. & Agami, R. Alternative cleavage and polyadenylation: Extent, regulation and function. *Nature Reviews Genetics* (2013). doi:10.1038/nrg3482
83. Tian, B. & Manley, J. L. Alternative polyadenylation of mRNA precursors. *Nat. Rev. Mol. Cell Biol.* **18**, 18–30 (2016).
84. Goulet, I., Boisvenue, S., Mokas, S., Mazroui, R. & Côté, J. TDRD3, a novel Tudor domain-containing protein, localizes to cytoplasmic stress granules. *Hum. Mol. Genet.* **17**, 3055–3074 (2008).
85. Liu, P., Sanalkumar, R., Bresnick, E. H., Keleş, S. & Dewey, C. N. Integrative analysis with ChIP-seq advances the limits of transcript quantification from RNA-seq. *Genome Res.* **26**, 1124–1133 (2016).
86. Newman, J. R. B., Concannon, P., Tardaguila, M., Conesa, A. & McIntyre, L. M. Event Analysis: Using Transcript Events To Improve Estimates of Abundance in RNA-seq Data. *G3:Genes|Genomes|Genetics* **8**, 2923–2940 (2018).
87. Grillo, G. *et al.* UTRdb and UTRsite (RELEASE 2010): A collection of sequences and regulatory motifs of the untranslated regions of eukaryotic mRNAs. *Nucleic Acids Res.* (2009). doi:10.1093/nar/gkp902
88. Tempel, S. Using and understanding repeatMasker. *Methods Mol. Biol.* **859**, 29–51 (2012).
89. Dweep, H. & Gretz, N. miRWalk2.0: a comprehensive atlas of microRNA-target interactions. *Nat. Methods* **12**, 697–697 (2015).
90. Agarwal, V., Bell, G. W., Nam, J.-W. & Bartel, D. P. Predicting effective microRNA target sites in mammalian mRNAs. *Elife* **4**, (2015).
91. Enright, A. J. *et al.* MicroRNA targets in Drosophila. *Genome Biol.* **5**, R1 (2003).
92. Kozomara, A. & Griffiths-Jones, S. MiRBase: Annotating high confidence microRNAs using deep sequencing data. *Nucleic Acids Res.* **42**, (2014).
93. Yang, Y. C. T. *et al.* CLIPdb: A CLIP-seq database for protein-RNA interactions. *BMC Genomics* **16**, (2015).
94. Quevillon, E. *et al.* InterProScan: Protein domains identifier. *Nucleic Acids Res.* **33**, (2005).
95. Krogh, A., Larsson, B., Von Heijne, G. & Sonnhammer, E. L. L. Predicting transmembrane protein topology with a hidden Markov model: Application to complete genomes. *J. Mol. Biol.* **305**, 567–580 (2001).
96. Petersen, T. N., Brunak, S., von Heijne, G. & Nielsen, H. SignalP 4.0: discriminating signal peptides from transmembrane regions. *Nat. Methods* **8**, 785–786 (2011).
97. Lupas, A., Van Dyke, M. & Stock, J. Predicting coiled coils from protein sequences. *Science (80-.).* **252**, 1162–1164 (1991).
98. Kosugi, S., Hasebe, M., Tomita, M. & Yanagawa, H. Systematic identification of cell cycle-dependent yeast nucleocytoplasmic shuttling proteins by prediction of composite motifs. *Proc. Natl. Acad. Sci.* **106**, 10171–10176 (2009).
99. Necci, M., Piovesan, D., Dosztanyi, Z. & Tosatto, S. C. E. MobiDB-lite: Fast and highly specific consensus prediction of intrinsic disorder in proteins. *Bioinformatics* **33**, 1402–1404 (2017).
100. Zhang, Z. *et al.* Noisy splicing, more than expression regulation, explains why some exons are subject to nonsense-mediated mRNA decay. *BMC Biol.* **7**, (2009).
101. UniProt Consortium, T. U. The Universal Protein Resource (UniProt). *Nucleic Acids Res.* (2007). doi:10.1093/nar/gkl929
102. Hornbeck, P. V. *et al.* PhosphoSitePlus, 2014: Mutations, PTMs and recalibrations. *Nucleic Acids Res.* **43**, D512–D520 (2015).
103. Pauws, E. Heterogeneity in polyadenylation cleavage sites in mammalian mRNA sequences:

implications for SAGE analysis. *Nucleic Acids Res.* **29**, 1690–1694 (2001).
104. Fisher, R. A. On the Interpretation of χ 2 from Contingency Tables, and the Calculation of P. *J. R. Stat. Soc.* **85**, 87–94 (1922).
105. Benjamini, Yoav ; Hochberg, Y. Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B-Methodological 1995.pdf. *J. R. Stat. Soc. Ser. B* **57**, 289–300 (1995).
106. Nueda, M. J., Tarazona, S. & Conesa, A. Next maSigPro: Updating maSigPro bioconductor package for RNA-seq time series. *Bioinformatics* **30**, 2598–2602 (2014).
107. Ha, K. C. H., Blencowe, B. J. & Morris, Q. QAPA: A new method for the systematic analysis of alternative polyadenylation from RNA-seq data. *Genome Biol.* (2018). doi:10.1186/s13059-018-1414-4
108. Tarazona, S. *et al.* Data quality aware analysis of differential expression in RNA-seq with NOISeq R/Bioc package. *Nucleic Acids Res.* **43**, (2015).
109. Nueda, M. J., Martorell-Marugan, J., Martí, C., Tarazona, S. & Conesa, A. Identification and visualization of differential isoform expression in RNA-seq time series. *Bioinformatics* **34**, 524–526 (2018).
110. McIntyre, L. M. *et al.* Sex-specific expression of alternative transcripts in Drosophila. *Genome Biol.* **7**, R79 (2006).
111. Gonzàlez-Porta, M., Frankish, A., Rung, J., Harrow, J. & Brazma, A. Transcriptome analysis of human tissues and cell lines reveals one dominant transcript per gene. *Genome Biol.* **14**, R70 (2013).
112. Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. *BMC Bioinformatics* **12**, 323 (2011).

Supplementary material



Supplementary Figure 1: tappAS visualization of functional feature variation across isoforms. A) The *Rbm4* gene presents transcript-level variation in the inclusion of a GU-rich element (GRE) in the 3'UTR due to an exon-skipping event. B) Transcript-level variation in one of the isoforms of the *Tcf12* gene, which includes a 3'UTR region enriched in GREs due to an alternative Transcription Termination Site.



Supplementary Figure 2: DE and DIU analysis results. A) Two examples of genes (*Acot11* and *Arl8*) detected as false positives for Differential Isoform Usage after minor isoform filtering (% expression < 0.1), i.e. where removal of the minor isoform leads to no DIU status. Filtered isoforms are indicated by arrows. B) Expression charts and tappAS visualization of annotated functional features at the transcript (left) and protein (right) levels for the *Mynn* gene, where Differential Isoform Usage and major isoform switching imply no Differential Coding sequence Usage.



Supplementary Figure 3. A) Clustering of GO term enrichment results for DE genes**.** Clusters are generated according to the similarities of significantly enriched GO terms. The color-coded legend indicates global process labels assigned after inspection of the different GO terms integrating each cluster. Important functions enriched in DE genes, i.e. affected by Differential Expression due to phenotypic differences between NSC and Oligodendrocytes, include ion/calcium homeostasis, cell motility and lipid metabolism. Circle size indicates enrichment Fisher Exact Test adjusted p-value. B) Relative functional relevance between DE and DIU regulation obtained in Multi-Dimensional Gene Set Enrichment Analysis of DE and DIU genes, representation of neural-related terms. Nodes correspond to GO-terms obtained by selecting the top-10 terms ranked by significance in the DE enrichment and the top-10 terms ranked by significance in the DIU enrichment (from a list of all neural-related GO-terms). Pie chart area represents DE and DIU regulation, and corresponds to relative -log10(p-value).


A
Srsf5
DIU p-value = 0,017
Total change = 20,99
DCU p-value = 0,066
Total change = 17,09
Srsf5 - Gene Expression
Srsf5 - Transcript Expression
Srsf5 - CDS Expression
Expression Level
Experimental Group
NSC
OLD
Srsf5
PB.1636.1 PB.1636.2 PB.1636.3 PB.1636.4 PB.1636.5 PB.1636.6 PB.1636.7
novelProt237 O35326 Q9D8S5
B
Srsf10
DIU p-value = 6e-4
Total change = 21,54
DCU p-value = 0,0038
Total change = 22,11
Srsf10 - Gene Expression
Srsf10 - Transcript Expression
Srsf10 - CDS Expression
Srsf10
PB.5182.1 PB.5182.2 PB.5182.3 PB.5182.4
PB.5182.5 PB.5182.6 PB.5182.7 PB.5183.1
novelProt1867 novelProt3558 Q9R0U0
Q9R0U0-3 XP_011248490.1
C
Mbnl2
DIU/DCU p-value = 7e-5
Total change = 27,22
Mbnl2 - Gene Expression
Mbnl2 - Transcript Expression
Mbnl2 - CDS Expression
Mbnl2
PB.2287.1 PB.2287.2 PB.2287.4 PB.2288.1
Q8C181 Q8C181-2 Q8C181-4
D
Rbm5
DIU/DCU p-value = 0,017
Total change = 21,32
Rbm5 - Gene Expression
Rbm5 - Transcript Expression
Rbm5 - CDS Expression
Rbm5
PB.7464.10 PB.7464.11 PB.7464.12 PB.7464.2
PB.7464.3 PB.7464.4 PB.7464.6 PB.7464.9
novelProt2311 novelProt4392 novelProt4747 novelProt5160
Q91YE7 XP_006511937.1 XP_006511938.1
E
Rbm7
DIU/DCU p-value = 2e-5
Total change = 34,25
Rbm7 - Gene Expression
Rbm7 - Transcript Expression
Rbm7 - CDS Expression
Rbm7
PB.7227.1 PB.7227.2
Q3U5M9 Q9CQT2

Supplementary Figure 4: Splicing factors regulated by DIU. Transcript, gene and protein expression levels providing evidence of DIU status and self-regulation of the AltTP machinery: A) *Srsf5*, B) *Srsf10*, C) *Mbnl2*, D) *Rbm5*, E) *Rbm7*. DIU and/or DCU (indicated only when significantly different from DIU results) significance corresponds to multiple testing adjusted Q-Values.



Supplementary Figure 5: *Mbnl1* AltTP results. A) Gene, transcript and CDS expression for *Mbnl1*. The gene is positive for DIU both at the transcript and protein level. B) tappAS visualization of *Mbnl1* functional annotation. Differential inclusion of an NLS signal is detected by tappAS comprehensive annotation. C) DFI results for *Mbnl1* NLS signal. The feature is significantly differentially included, and favoured in NPCs. D) Western blot analysis of *Mbnl1* in cytosolic and nuclear fractions of NPCs and OPCs. Together with a general increase in *Mbnl1* expression in OPCs (INPUT), an increase in protein levels in the cytoplasm is observed, likely due to exclusion of the NLS signal (Cytosolic fraction).



Supplementary Figure 6: potential AltTP regulation of Mbd1 in DNA binding properties. A) Protein-level functional features annotated in tappAS. Highlighted area indicates differential inclusion of a third CXXC zinc finger domain to the coding region. B) DFI results for the CXXC zinc finger domain in the *Mbd1* gene. Inclusion of the domain, together with a general upregulation of *Mbd1*, are observed. C) Gene, transcript and CDS-level expression of *Mbd1*. The gene presents DE, DIU and DCU status.

A


Rbm39 - RNA binding motif protein 39
Proteins View - Aligned
Q8VH51-2
XP_011237624.1
Q8VH51-3
Q8VH51
UniProtKB/Swiss-Prot_Phosphosite : MOTIF
UniProtKB/Swiss-Prot_Phosphosite : PTM
UniProtKB/Swiss-Prot_Phosphosite : COMPBIAS
MOBIDB_LITE : DISORDER
cNLS_mapper : MOTIF
PFAM : DOMAIN - PF15519
PFAM : DOMAIN - PF00076
Co-inclusion of IDR, NLS and phosphoserine sites

B


Papola - Poly (A) polymerase alpha
Proteins View - Aligned
E9PZR3
Q61183
novelProt1898
novelProt1470
UniProtKB/Swiss-Prot_Phosphosite : PTM
UniProtKB/Swiss-Prot_Phosphosite : BINDING
UniProtKB/Swiss-Prot_Phosphosite : MOTIF
MOBIDB_LITE : DISORDER
TMHMM : TRANSMEM
cNLS_mapper : MOTIF
PFAM : DOMAIN - PF04926
PFAM : DOMAIN - PF01909
PFAM : DOMAIN - PF04928
Co-inclusion of IDR, NLS and phosphoserine sites

C


Zfp64 - Zinc finger protein 64
Proteins View - Aligned
A2AQR3
A2AQR4
MOBIDB_LITE : DISORDER
cNLS_mapper : MOTIF
PFAM : DOMAIN - PF13909
PFAM : DOMAIN - PF00096
PFAM : DOMAIN - PF12874
PFAM : DOMAIN - PF13912
Co-inclusion of C2H2-type zinc finger domains and NLS motifs

D


Zfp354b - Zinc finger protein 354B
Proteins View - Aligned
Q9QXT9
novelProt963
UniProtKB/Swiss-Prot_Phosphosite : BINDING
UniProtKB/Swiss-Prot_Phosphosite : PTM
MOBIDB_LITE : DISORDER
cNLS_mapper : MOTIF
PFAM : DOMAIN - PF16622
PFAM : DOMAIN - PF13894
PFAM : DOMAIN - PF00096
PFAM : DOMAIN - PF01352
Co-inclusion of C2H2-type zinc finger domain and a NLS motif

Supplementary Figure 7: co-DFI results examples. A) Variation in the inclusion of protein-level functional elements in the *Rbm39* gene, which presents co-DFI status for an Intrinsically Disordered Region (IDR, DISORDER), several phosphoserine residues (PTM) and a Nuclear Localization Signal (NLS, MOTIF). B) Protein-level functional elements in the *Papola* gene, which presents co-DFI status for an IDR (DISORDER), several phosphoserine residues and two NLS (MOTIF). C) Protein visualization of he *Zfp64* gene, which presents co-DFI status of several C2H2-type zinc finger domains (PF13912, PF00096 and PF13909) and NLS motifs. D) The *Zpf354b* gene presents co-DFI status of a C2H2-type zinc finger domain (PF00096) and an NLS motif.

Annotation level	Source	Category	No. feature occurrences	No. isoforms annotated
Transcript 11970 isoforms 7167 genes	ScanForMotifs	PAS	8511	5750 (48%)
	ScanForMotifs	3'UTR motifs	11797	5325 (44%)
	UTRscan/UTRsite	5'UTR motifs	325	315 (3%)
	UTRscan/UTRsite	uORF	7444	3045 (25%)
	RepeatMasker	Repeat regions	19269	7245 (61%)
	MiRWalk/miRbase + in-house scripts	3'UTR miRNA binding sites	106392	9474 (79%)
	clipDB + in-house scripts	RNA-binding sites (RBPs)	47821	7279 (61%)
Protein 10813 coding isoforms 7167 genes	In-house scripts	Nonsense-Mediated Decay (NMD)	329	329 (3%)
	PFAM-HMMER3	Domains	20973	9608 (89%)
	COILS + UniprotKB	Coiled coil	6669	2856 (26%)
	TMHMM + UniprotKB	Transmembrane regions	12543	2061 (19%)
	SignalP	Signal peptides	824	824 (8%)
	MOBIDB	Disordered regions	11256	5626 (52%)
	cNLS mapper + UniprotKB	Nuclear Localization Signals (NLS)	7599	4297 (40%)
	PSP + UniprotKB	Post-Translational Modifications (PTM)	100804	8506 (79%)
	UniprotKB	Compositional bias	2260	1480 (14%)
	UniprotKB	Motif	6579	2897 (27%)
	UniprotKB	Intramembrane	159	62 (0.6%)
	UniprotKB	Active site	1770	1168 (11%)
	UniprotKB	Binding	12790	3339 (31%)

Supplementary Table 1: summary of annotation results for the mouse transcriptome of NPC and OPC primary cells. Number of features at the transcript and protein levels annotated are indicated, together with their database of origin and the percentage of isoforms in the transcriptome that contain them.

3′ UTR motif	p-value	Adj.p-value	No. varying genes (%)
GU-rich Destabilization Element	0.0024	0.05	197 (69.4%)
GU-Rich Element (GRE)	0.0281	0.33	243 (66.2%)
tRNA-like structure	0.079	0.53	279 (64.7%)
Brd-Box	0,088	0.53	189 (65.4%)
Dinucleotide Repeat	0.283	1	32 (66.6%)

Supplementary table 2: ID-level FDA results for UTR motifs, top 5 ranked by adjusted p-value. Significance assessed via Fisher's Exact Test with Bonferroni-Hochberg multiple-testing correction.

miRNA	p-value	Adj.p-value	No. varying genes (%)
mmu-miR-335-3p	9e-4	0.46	61 (62.2%)
mmu-miR-590-3p	0.0059	0.77	83 (56.8%)
mmu-miR-880-3p	0.0071	0.77	21 (70%)
mmu-miR-7b-3p	0.0101	0.77	43 (60.5%)
Mmu-miR-223-3p	0.0145	0.77	35 (61.4%)

Supplementary table 3: ID-level FDA results for miRNA binding motifs, top-5 ranked by adjusted p-value. Significance assessed via Fisher's Exact Test with Bonferroni-Hochberg multiple-testing correction.

Methods

Retrieving isoform-resolved functional annotation features

tappAS uses a gff3 like file with transcript structural and functional data. To produce this file for our mouse data (Supplementary Table 1) we use available databases and state-of-the-art prediction algorithms. Features are gathered through two mechanisms: positional transfer from functional databases and *de novo* prediction by state-of-the-art algorithms for sequence-based function prediction. All functional labels annotated at the isoform resolution are positionally described via their exact localization within protein/RNA molecules.

RNA-level annotations included: cis-acting UTR regulatory elements and Upstream Open Reading Frames (uORFs) predicted by UTRscan[87]; repeat regions and low-complexity elements predicted by repeatMasker[88]; and miRNA binding sites collected from mirWalk2.0[89]. A minimum seed length of 7bp and a p-value threshold of 0.05 were set as requirements to call miRNA binding sites. We filtered the site list by the number of sources reporting the association, requiring that miRNA binding sites to be predicted by a minimum of 5 methods, among which Targetscan[90], miRanda[91], and mirWalk[89] are required. mirWalk provides transcript coordinate information to locate miRNA binding sites. High confidence miRNAs can be identified using the experimental evidence information in miRBase[92]. In our example there were 511 miRNAs with annotated binding sites and experimental evidence. Binding sites for RNA-binding proteins (RBPs) can be annotated by collecting genomic crosslinking immunoprecipitation (CLIP) data from CLIPdb[93] and mapping sites to isoforms. RNA

binding sites can be transferred by user defined levels of stringency. For our example, we required prediction by at least two algorithms in CLIPdb.

At the protein level, Pfam domains are mapped with InterProScan[94], transmembrane regions predicted with TMHMM[95], signal peptides obtained by SignalP 4.0[96], coiled-coil regions predicted by COILS[97], single and bipartite Nuclar Localization signals mapped by cNLS mapper[98] (score > 6) and disordered regions obtained by MobiDB Lite[99], which derives consensus IDR predictions by combining 8 different predictors. We predicted isoforms containing a premature termination codon (PTC) -potentially leading to nonsense-mediated decay (NMD)- using the 50-NT rule[100] that indicates that a termination codon situated more than 50-55 nt upstream of an exon-exon junction is generally a PTC.

In addition to sequence-based prediction methods, some protein-centric databases contain a detailed annotation of protein features. However, these are generally biased towards the annotation of the best-documented isoform, hindering the study of the functional diversity of alternative isoforms. To correct this, we map canonical isoform annotations to query isoform sequences, novel or known, following an isoform-aware positional transfer strategy. We obtained the information on protein functional features by parsing UniprotKB[101] and PhosphoSitePlus[102] databases. In both cases we deal with the disparities between databases when defining gene models and ensure the ORF and genomic position conservation between public and query sequences during feature transference. As a result, we retrieved an extensive set of post-translational modification (PTM) sites with experimental evidence from

PhosphoSitePlus, and a diverse catalogue of functional sequence features from UniprotKB.

tappAS contains precomputed gff3 files with isoform functional data for mouse, human, Arabidopsis, fly and maize. Specific details can be found in Supplementary Table 1.

Visualization engine of positional functional annotation at isoform resolution

The tappAS visualization engine is designed to display isoform variability in a user-friendly manner, and constitutes one of the most useful features of the application. Using the visualization power of the Java engine, tappAS displays the whole catalogue of isoform-resolved annotation features and their position using a distinctive icon on both transcript and protein isoform structure maps. Maps include UTR/CDS areas, polyA sites, splice junction and exon information, and functional features, creating a graphical representation that greatly facilitates the study and comparison of isoform diversity.

Functional Diversity (FD) Analysis

Isoforms vary in structural and functional features among isoforms of the same gene. FD identifies and measures the nature of the variability in a qualitative manner. For every annotated feature, all pairwise comparisons between transcript isoforms from

the same gene are performed and a gene is labelled as *varying* if at least one isoform pair has variability in a feature, either in its annotated genomic position(s) (*Positional Varying*) or in the presence/absence of the annotated feature (*Presence Varying*). Functional Diversity can be assessed by gene or by feature ID.

Gene-Level Diversity

The Gene-Level Diversity analysis evaluates genes as a function of the structural, functional and regulatory feature categories that are modulated by AltTP. Depending on the feature category and its relationship to the functional properties of a transcript or protein, Functional Diversity is evaluated using a *Positional Varying* strategy or a *Presence Varying* strategy.

The *Positional Varying* approach compares features by genomic position, i.e. by mapping features to genomic coordinates and classifying them as varying if coordinates are not equivalent between gene isoforms. Position disagreement is annotated when >9bp, that is, 3 amino acids, allowing for variability in prediction. In contrast, *Presence Varying* includes only presence/absence of annotation. For instance, NMD transcript status is is, based differences in the transcript level NMD label. In contrast, transcript attributes such as UTR length, CDS and polyA site positions, are examples of features where *positional* evaluation is meaningful. However, a third group of features (such as Pfam domains or transmembrane regions) can be affected by AltTP via both complete and partial disruption of the feature. In these and similar cases, both strategies can be used, and provide

complementary insight on AltTP in the potential regulation of the functional or regulatory feature.

For structural features evaluated by *Positional Varying*, some special considerations are required. In order to detect alternative polyadenylation (APA) events, polyA sites are identified as the last genomic position of transcript isoforms and evaluated in a pairwise manner by computing the polyA distance between each pairwise combination of isoforms expressed by a given gene. mRNA cleavage is not an exact process and can occur within a small window of positions[103]. To take cleavage variability into account, tappAS' FD analysis labels a pair of isoforms as APA when there is a minimum X bp genomic distance (default value 100) between polyA sites. UTR length is computed for each isoform for subsequent pairwise comparison between coding isoforms from the same gene. Pairs of isoforms with 3'/5' UTR differences above a user-specified cutoff (75 bp by default) are labelled as 3'/5' UTR length varying, respectively. Finally, CDS variability is determined by comparing CDSs both at the sequence and genomic coordinate levels. Non-coding isoforms are discarded from CDS diversity analysis.

Feature-Level Diversity

The Feature-Level Diversity analysis identifies specific functional and regulatory elements (i.e. by feature ID instead of source/functional category) varying across isoforms from the same gene. Feature-Level Diversity Analysis counts the number of genes for which a given feature ID is flagged as *varying* in the gene level analysis. The diversity status of each ID can be evaluated via *Positional, Presence Varying* or both.

The significance level of every feature global variation across genes is evaluated using Fisher's Exact Test[104], and then corrected using the Benjamini-Hochberg[105] method for multiple testing correction.

Differential Feature Inclusion (DFI) analysis

DFI applies the concept of exon inclusion analysis to functional features. DFI is only applied to features labelled as varying –either by position or as present/absent- across each gene's isoforms, as only these have the potential to be significantly regulated. For a given gene and functional element, the null hypothesis that transcripts containing the feature have equivalent expression to transcripts not containing the feature is tested for each gene. Expression values of the isoforms containing the feature, and isoforms where the feature is not present are calculated from the data.

The *feature inclusion rate* is the ratio between the sum of expression of all feature-including isoforms and the total expression of the gene (i.e. sum of expression of isoforms including and excluding the feature) for each condition studied:

$$\mathrm{FI_{fg}} = \frac{\mathrm{EInc_{fg}}}{\mathrm{EInc_{fg}} + \mathrm{EExc_{fg}}}$$

where *EInc* is the aggregated expression value for feature-including isoforms and *EExc* is the aggregated expression value for feature-excluding isoforms for gene *g* and positional feature *f*.

Differential inclusion of functional features is then tested using generalized linear models adapting DEXSeq[6] and maSigPro[106] methods, for case-control and time-course experimental designs, respectively. For each feature *f* and gene *g*:

$$h(\mu_{fg}) = \beta_0 + \beta_1 C_{fg} + \beta_2 T_{fg} + \beta_3 F_{fg} + \beta_4 C_{fg} F_{fg} + \beta_5 C_{fg} T_{fg} + \beta_6 F_{fg} T_{fg} + \beta_7 C_{fg} F_{fg} T_{fg}$$

where *h* is the link function of the GLM, $\mu_{fg}=E(y_{fg})$ is the expected aggregated expression level, C_{fg} is the binary variable that identifies each of the two experimental conditions, T_{fg} is the time point, and F_{fg} is the binary variable that identifies the variant (Feature-Excluding or Feature-Including).

Each gene and feature are individually modeled. For each model, the significance of the condition-variant or condition-variant-time interactions is evaluated, depending on the experimental design considered. When multiple functional annotation categories are analyzed (domains, UTR motifs, disordered regions, etc.), each of them is tested independently. P-values are corrected by FDR and significance is set to 0.05 by default.

Co differential feature inclusion analysis (Co-DFI)

Co-DFI analysis evaluates how frequently two features are simultaneously DFI for the same gene in the same condition, while mutual exclusion evaluates how often two features are simultaneously DFI for the same gene in the different condition. Co-DFI is computed for each pair of features detected as DFI in at least 5 genes.

Defining a library of polyA sites

tappAS uses a polyA site database is created by extracting the genomic coordinate of the last position of each transcript isoform. Unlike recently developed tools[107], polyA sites in terminal exons with different 5′ start sites are also considered to allow the analysis of Alternative PolyAdenylation sites affecting either Coding (CR-APAs) or UTR- (UTR-APAs) events. Non-coding isoforms as well as NMD-predicted variants are discarded.

Next, a series of filtering and collapsing steps are performed in order to define the proximal (pPA) and distal polyA (dPA) site for each gene. First, independent cleavage sites are defined by merging polyA sites located within a 75 bp window. To avoid the definition of a minor polyA site as a distal or proximal site, a filtered based on relative polyA site expression levels is applied and only polyA sites accumulating at least 10% (default threshold) of total gene expression in at least one condition are considered. In the case of genes with more than two polyA sites, we perform a final merge of unlabelled sites by assigning them to the nearest proximal or distal site.

Differential Polyadenylation Analysis (DPA)

Using the defined polyA site library, tappAS computes the per-gene and per-sample dPA and pPA site expression levels by collapsing the expression levels of the set of transcript isoforms that contain either the dPA or de pPA. The same GLM model used for DFI is applied to capture significant condition-variant interactions. The relative distal polyA site usage (DPAU) is implemented by calculating the relative expression

of the sum of all isoforms containing the distal site over the total polyA site expression level of the gene:

$$\mathrm{DPAU} = \frac{\mathrm{E_{dPA}}}{\mathrm{E_{dPA}} + \mathrm{E_{pPA}}}$$

where *EdPA* and *EpPA* to the expression levels of the variants defined as distal and proximal polyA sites.

Detecting lengthening and shortening of 3' UTRs

For isoforms with identical CDS end positions but different polyA (UTR-APAs) distal/proximal polyA site usage directly associates with UTR lengthening/shortening events. However, when changes in polyA site position imply changes in the CDS (CR-APAs), it is impossible to directly infer the relationship between the polyA site and 3' UTR length. Since DPA analysis assesses polyA site regulation independently of the coding sequence, tappAS introduces a specific 3' UTR lengthening/shortening analysis by computing an isoform usage-weighted mean UTR length for each condition:

$$\mathrm{UTR_w} = \frac{\sum_{i=1}^{n} \mathrm{U_{ig}} \cdot \mathrm{UTR_{ig}}}{\sum_{i=1}^{n} \mathrm{UTR_{ig}}}$$

where *U* is the relative usage of isoform *i* in gene *g* and *UTR* its associated 3' UTR length.

UTRs from highly expressed isoforms will contribute in a higher proportion to the final UTR mean length. The weighted UTRs is a measure of the actual extent of UTR length changes across conditions. Statistical differences are tested by using a Wilcoxon rank-sum test of the weighed UTR values.

tappAS software

tappAS (http://tappas.org) is a Java GUI application that provides a broad analytical framework including a range of functions that, collectively and in combination allow the study of different structural and functional aspects associated to isoform usage. Statistical methods are implemented in R and are run by tappAS using the Rscript environment. See http://tappas.org for a comprehensive list of R package dependencies, as well as other software and hardware requirements.

tappAS uses a gff3-like file containing functional annotations at the isoform level, as described above. Structural information, including annotation of UTRs, CDS and introns, together with gene, protein and transcript reference IDs for each transcript sequence are also represented in the this gff3-like file. Currently, annotation files for Human (ENSEMBL and RefSeq databases), Mouse (ENSEMBL and RefSeq databases), Drosophila, Arabidopsis and Maize are available in the tappAS application. Users can optionally input their gff3 files.

tappAS works as a compendium of independent projects, each of them created using two inputs: a transcript expression matrix and an experimental design file, that can either be a case-control or a time-course experiment. Being a GUI application, tappAS also provides a rich set of interactive features via the JavaFX platform, including customizable data tables, complex sorting and filtering options, data and figure export, context-sensitive help pages, data drill-down and display customization.

tappAS is designed an open framework and accepts user-defined gene lists as input for analysis.

While tappAS accepts a transcript-expression file, it uses the structural annotation included in the gff3 to estimate the expression of genes, as the sum of their transcript expression, and CDSs, as the sum of transcripts having the same ORF. Differential expression analyses can be then run at each of these aggregation levels.

The application includes the analysis methods described above and implements existing tools when appropriate, including NOISeq[108] and maSigPro[106] for differential gene expression; DEXseq[6] and Iso-maSigPro[109] for differential isoform usage. These two methods assess DIU by fitting generalized linear models (GLMs) and testing the significance of the isoform-condition interaction coefficient, as proposed in[110]. Implemented enrichment methods are GOSeq[58] (Functional Enrichment) GOglm[59] (Gene Set Enrichment) and mdgsa[69] for multi-dimensional GSE. These enrichment tools can be easily applied to the results of any of the statistical methods included in tappAS. Finally, tappAS implements extant complementary functionalities (i.e. low-count expression filtering, TMM normalization, PCA, clustering methods) that enable the pre-processing and flexible exploration of data and results.

Complementary metrics for isoform analysis

tappAS incorporates complementary analysis features and metrics specially conceived for a better assessment of the functional implications of AltTP.

a) Major and minor isoforms

In tappAS, the major isoform of a gene is defined as the isoform with the highest mean expression across all conditions of the study, while other isoforms of the gene are labelled minor forms. Such definition is operational in the context of tappAS analysis and does not assume functional relevance or expression levels in other experimental settings.

b) Isoform prefiltering

Genes in mammalian transcriptomes usually express multiple of isoforms. However, frequently only one or few of them accumulate the major proportion of gene expression[111] while remaining isoforms, although detected, have low expression levels. Although tappAS allows for low expression filtering upon data upload, still isoforms may remain that are relatively minor for their gene expression level. When the minor isoforms have small expression changes between conditions, but these occur in the opposite direction to the predominant isoforms, significant isoform-condition coefficients may appear at GLM models. To avoid the detection of DIU genes because of the 'flat' behaviour of minor isoforms, an isoform filtering step can be applied before statistical modeling. Two filtering approaches are implemented in tappAS. One considers the proportion of a gene's expression represented by each isoform and filters those that do not reach a minimum expression rate (10% by default), while the other calculates the fold-change of the minor isoforms versus the major to remove those below a specified fold-change (FC) threshold (default FC=2). Users can use which filtering option to apply

c) Total usage change

Total usage change in DIU analysis

The Fold Change is a measure magnitude in of differential expression that cannot be easily applied to DIU analysis, where multiples isoforms are tested in a single model. Instead, we propose a new metric, *total usage change* to quantify the magnitude of change for DIU genes. *Total usage change* measures the amount of redistribution (as %) in expression levels across different conditions for isoforms of the same gene. Because absolute gene expression levels may be different across conditions, total change values are always represented as a function of the gene expression FC.

We define isoform usage as the relative expression of isoform *i* in gene *g*. Then, total usage change can be defined as:

$$\sum_{i=1}^{n} \left| \overbrace{\frac{E_{1ig}}{\sum_{i=1}^{n} E_{1ig}}}^{\text{IsoformUsageC1}} - \overbrace{\frac{E_{2ig}}{\sum_{i=1}^{n} E_{2ig}}}^{\text{IsoformUsageC2}} \right| \times 0.5$$

where E_{ig} is the expression value for isoform *i* and gene *g*.

Defining total usage change for feature analyses

When performing DFI and DPA analyses, expression values are collapsed to obtain feature inclusion (FI) and distal polyadenylation site usage (DPAU) levels. In this case, total change is re-defined as the redistribution (as %) of FI (ΔFI) or DPAU (ΔDPAU) levels across every pair of conditions considered. Note that both metrics are also dependent on absolute expression.

d) Defining switching events

Switching events are defined in order to identify Differential Feature Inclusion, Differential Polyadenylation and Differential Isoform Usage events that imply a strong change and prioritize candidates for further analysis.

A *major isoform switching event* occurs when the major isoform of gene the becomes minor at one particular condition. In multiple time-course series major isoforms are defined for each experimental group and so is the major isoform switch. *Feature switching* (in DFI) and *distal polyA usage switching* (in DPA) are similarly defined.

Favored conditions

In DPA and DFI analyses, switching information is complemented by information of the favored condition, i.e. the experimental condition where the inclusion of the feature is promoted.

Experimental setup in murine neural cells

As proof-of-concept of our analysis framework, we used the data in Tardaguila et al[57]. Briefly, two different cell types: Neural Precursor Cells (NPC) and Oligodendrocyte Progenitor Cells (OPCs) had expressed transcriptomes estimated using PacBio Iso-Seq sequencing and curated by SQANTI[57], resulting in 11,970 transcripts coded by 7,167 genes. We computed isoform expression levels with RNA-seq using RSEM[112] following ENCODE guidelines

Validation of events with potential functional impact

Western Blot

We validated AltTP-mediated localization changes via differential inclusion of Nuclear Localization Signals (Ctnnd1, Mbnl1) using nucleus-cytoplasm fractioning and western blot analyses. Total protein fraction was extracted from cell cultures using lysis buffer containing 50 mM Tris-HCl, pH 7.5,150 mM NaCl, 0.02% NaN3, 0.1 SDS, 1% NP40, 1 mM EDTA, 2 mg/mL leupeptin, 2 mg/mL aprotinin, 1 mM PMSF, 1x Protease Inhibitor Cocktail (Roche Diagnostics, San Diego, CA, USA). The cytoplasmic and nuclear protein fractions were extracted with lysis buffer containing HEPES 10 mM pH 7.9, KCl 10 mM, EDTA 1 mM, EGTA 1 mM, DTT 1 mM, B-glycerophospate 10 mM and 1x Protease Inhibitor Cocktail (Roche Diagnostics, San Diego, CA, USA). IGEPAL (CA-630) 0.4% was then added and samples were vigorously vortexed and centrifuged at 12000g at 4ºC for 5 minutes. The supernatant (cytoplasmic fraction) was recovered, and the remaining pellets were incubated in lysis buffer containing 10 mM TRIS pH 7.4, NaCl 400 mM, IGEPAL (CA-630) 0.5%, EDTA 1 mM, EGTA 1 mM,DTT 1 mM, B-glycerophospate 10 mM and 1x Protease Inhibitor Cocktail (Roche Diagnostics, San Diego, CA, USA) to recover nuclear protein extracts (nuclear fraction). The protein concentrations of the supernatant were determined via bicinchoninic acid technique (Pierce® BCA protein assay; Thermo Fisher Scientific) and stored at -80C. Equal protein amounts were loaded, separated in 10% SDS–PAGE and transferred into a PVDF membrane. The membrane was blocked with 5% milk in TBS with 0.1% Tween-20 for 1h at room temperature and incubated at 4 °C overnight with the following primary antibody solutions (4% milk, 0,5% Tween-TBS): Anti p120 (Ctnnd1) 1:2000 (Millipore 05-1567, clone 15D2); Anti Mbnl1 1:100 (DSHB-MB2a(3b4)); Anti Ac H3 1:1000 (Millipore 06-599); Anti tubulin coupled HRP (Thermo MA5-16308-HRP). Membranes were incubated for 1h at room temperature with the

following secondary antibody dilutions (4% milk, 0,5% Tween-TBS): Anti mouse HRP (Life A16072) 1:10000; Anti rabbit HRP (Thermo 31460) 1:10000. Signal detection was performed with an enhanced chemiluminescence kit (ECL Plus Western blotting detection reagent from GE Healthcare, Piscataway Township, NJ, USA) and bands were detected using Alliance Q9 Advanced (Uvitec Cambridge Inc).